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Abstract
In the last decade, primarily through the use of sequencing, much has been learned about the trillions of
microorganisms that reside in human hosts. These microorganisms play a wide range of roles including
helping our immune systems develop, digesting our food, and protecting us from the invasion of
pathogenic organisms. My thesis focuses on the characterization of fungal, viral, and bacterial
communities in humans, investigating the use of defined microbial communities to cure diseases in
animal models, and examining the effects of human microbiome modifications through fecal microbiota
transfers. In the first part of this thesis, I use deep sequencing of ribosomal RNA gene tags to
characterize the composition of the bacterial, fungal, and archaeal microbiota in pediatric patients with
Inflammatory Bowel Disease and healthy controls. Archaeal reads were rare in the pediatric samples,
whereas an abundant amount of fungal reads was recovered. Pediatric IBD was found to be associated
with reduced diversity in both fungal and bacterial gut microbiota, and specific Candida taxa were
increased in abundance in the IBD samples. I, then, describe my use of a variety of experimental and
computational methods to study the viral communities of immune-compromised lung transplant
recipients. Anelloviruses, circular, single-stranded DNA viruses, were found in all lung samples but were
56 times more abundant in samples from lung transplant recipients as compared to healthy controls or
HIV+ subjects. In the third part of this thesis, I describe the use of defined microbial communities in mice,
and its ability to reduce the production of ammonia long term and mitigate hepatic encephalopathy. This
was shown to be true in both mice on a normal protein diet or a low protein diet. Last, I investigate the
transfer of viral communities between humans through FMT and characterize features associated with
efficient transmission. A case series where feces from a single donor were used to treat three children
with ulcerative colitis was used for the analysis. Ultimately this work showed that multiple viral lineages
do transfer between human individuals through fecal microbiota transplants, but in this case series none
of the viruses were known to infect human cells. In this thesis, I elucidate numerous roles for the
microbiome in pediatric patients with IBD and lung-transplant recipients, show exciting new finding about
engineering the microbiota to help with hyperammonia, and finally investigate a possible limitation about
using microbial communities as therapeutics. Together this body of work provides insights into the
assemblage of tiny organisms that live within us, constantly contributing.
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ABSTRACT

THE IMPACT OF TINY ORGANISMS: MICROBIAL COMMUNITIES AND DISEASE STATES
Christel Sjöland Chehoud
Frederic D. Bushman
Gary D. Wu

In the last decade, primarily through the use of sequencing, much has been learned about the
trillions of microorganisms that reside in human hosts. These microorganisms play a wide range
of roles including helping our immune systems develop, digesting our food, and protecting us
from the invasion of pathogenic organisms. My thesis focuses on the characterization of fungal,
viral, and bacterial communities in humans, investigating the use of defined microbial
communities to cure diseases in animal models, and examining the effects of human microbiome
modifications through fecal microbiota transfers. In the first part of this thesis, I use deep
sequencing of ribosomal RNA gene tags to characterize the composition of the bacterial, fungal,
and archaeal microbiota in pediatric patients with Inflammatory Bowel Disease and healthy
controls. Archaeal reads were rare in the pediatric samples, whereas an abundant amount of
fungal reads was recovered. Pediatric IBD was found to be associated with reduced diversity in
both fungal and bacterial gut microbiota, and specific Candida taxa were increased in abundance
in the IBD samples. I, then, describe my use of a variety of experimental and computational
methods to study the viral communities of immune-compromised lung transplant recipients.
Anelloviruses, circular, single-stranded DNA viruses, were found in all lung samples but were 56
times more abundant in samples from lung transplant recipients as compared to healthy controls
or HIV+ subjects. In the third part of this thesis, I describe the use of defined microbial
communities in mice, and its ability to reduce the production of ammonia long term and mitigate
hepatic encephalopathy. This was shown to be true in both mice on a normal protein diet or a low
protein diet. Last, I investigate the transfer of viral communities between humans through FMT
vi

and characterize features associated with efficient transmission. A case series where feces from
a single donor were used to treat three children with ulcerative colitis was used for the analysis.
Ultimately this work showed that multiple viral lineages do transfer between human individuals
through fecal microbiota transplants, but in this case series none of the viruses were known to
infect human cells. In this thesis, I elucidate numerous roles for the microbiome in pediatric
patients with IBD and lung-transplant recipients, show exciting new finding about engineering the
microbiota to help with hyperammonia, and finally investigate a possible limitation about using
microbial communities as therapeutics. Together this body of work provides insights into the
assemblage of tiny organisms that live within us, constantly contributing.
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CHAPTER 1: Introduction
The term “microbiome” was coined by Joshua Lederberg to describe the ecological
community of commensal, symbiotic, and pathogenic microorganisms that live in or on human
bodies (1). These trillions of microorganisms represent an ensemble of bacteria, archaea,
eukaryotes, and viruses. These organisms play important roles in human development,
physiology, immunity, disease, and nutrition. Many of these finding have been obtained over the
last decade, in part, thanks to the development of culture-independent sequencing technology
that allows us to investigate our microbial companions in an unbiased fashion. In this introductory
chapter, I provide an overview of sequencing-based microbiome research, the tools used in the
field, and the use of human stool for therapy of human disease.

Human Microbiome Project
The National Institute of Health launched the Human Microbiome Project (HMP) in 2008
(2). This $148 million endeavor sought to investigate the microbial diversity of 5 body sites:
mouth, nose, skin, vagina, and gut, in healthy American adults. As part of this initiative, they also
set out to sequence reference bacterial genomes, develop analytical and visualization tools, and
standardized protocols for the entire scientific community to use. The first phase of HMP’s work
was meant to, and has, served as the foundation for subsequent human microbiome work,
particularly when examining differences in microbial communities between healthy and diseased
individuals. The core questions of the HMP are: (1) is there a core human microbiome that is
shared by all humans; (2) is there a core set of microbial functions that are shared by all humans;
(3) to what extent does human phenotype or behavior impact the microbiome; (4) are changes in
the microbiome causing disease; and (5) can disease be treated by altering the microbiome (3) .
These questions have multi-faceted answers that we are still trying to answer today.
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Analytical Tools
Carl Woese revolutionized the field of microbiology when he described using the
sequence of the small subunit ribosomal RNA gene (rRNA) for phylogenetic identification of
organisms (4). The 16S rRNA, which is ubiquitously present in bacteria and archaea, and its 18S
rRNA counterpart in eukaryotes, became the main tool used by microbiologists to explore
microbial diversity and identify microorganisms throughout the body. DNA is typically isolated
from stool, the main surrogate for the gastrointestinal tract’s microbiome, or other body sites
including skin, vagina, and nose, and upper and lower respiratory tracts. 16S rRNA gene
sequences, typically 1300 to 1600 base pairs in length, contain both conserved regions, which
can be used for primer landing sites, as well as variable regions, which can be used for specieslevel identification (5, 6). This allows us to sequence a small part of a genome but identify an
entire organism.
16S rRNA gene sequencing is the most commonly used method to identify bacteria when
using amplicon-based sequencing. To identify archaeal sequences, 16S rRNA and rpoB genes
are typically used, while for fungal sequences, 18S rRNA and Internal Transcribed Spacers (ITS)
genes are commonly used. Since there is no gene ubiquitously present in all viruses, we cannot
perform targeted gene sequencing for viruses.
To perform amplicon-based sequencing, PCR reactions containing primers directed
against conserved regions of the targeted gene are used to generate amplicons that span both
the conserved and variable regions of the gene. Depending on the capacity of the sequencing
technology, the amplicons can span a different number of variable regions in the targeted gene.
The amplicons from each sample, which contain a unique barcode to distinguish the samples, are
pooled, sequenced, and computationally analyzed.
Computational analysis of targeted sequence data involves several stages. First, the
reads are grouped into operational taxonomic units (OTUs) based on sequence identity. A
representative sequence is used to represent each OTU, typically the most abundant sequence
2

or the longest sequence. OTUs can be defined at different sequencing similarity thresholds; for
example, a 97% OTU signifies that all of its member sequences are at least 97% similar based on
sequence identity. The representative OTU sequences are then aligned to reference sequences
and annotated using databases such as Greengenes or Ribosomal Database Project (7-10). The
alignments of the representative OTU sequences are also used to build a phylogenetic tree.
Popular distance metrics, such as Weighted and Unweighted Unifrac (11, 12), rely on the
phylogenetic distance between representative sequences when assessing differences in
samples’ microbial compositions. Distances, based on each sample’s quantity of sequences in
each OTU, are calculated and visualized using hierarchical clustering and ordinations (13).
As sequencing technology continues to improve, efforts have moved from targeted
amplification of select genes to shotgun sequencing of entire microbial communities.
Metagenomics refers to the untargeted sequencing and analysis of DNA from a mixture of
organisms. This is particularly useful since it can provide insight into the community’s gene
content and corresponding pathways and metabolites. This technique involves randomly sheering
DNA fragments and sequencing the resulting fragments (14). These resulting reads can be
queried independently or assembled into contigs. The reads or contigs can be compared to
databases of known genes including KEGG and COG (15-17). Programs such as metaphlan2
utilize unique clade-specific marker genes to match reads to specific bacteria, archaea,
eukaryotes and viruses (18). The resulting microbial community composition of each sample can
be visualized with heatmaps, to assess abundance or proportional abundance of the
microorganism present, or compared using hierarchical clustering and ordinations.
A major limitation to these methods is that we can only identify organisms that have been
previously identified and placed into databases. A way to circumvent this is to use the contigs, or
assembled genomes from reads. This is particularly common in the case of viruses. For viral
analysis, we typically use experimental techniques to filter out human and bacterial cells prior to
DNA extraction. After we have isolated DNA, we check for contaminating human and bacterial
3

DNA by quantifying beta-tubulin and 16S rRNA genes respectively. This ensure that there are at
most low levels of human and bacteria DNA, so that the sample is mostly viral DNA (19). Then,
after we have performed the sequencing, we take the resulting reads and assemble them into
contigs through traditional overlap consensus methods (20), de Bruijn graph assembly (21, 22) or
self-organizing map binning (23-25). Using the assembled contigs from all of the samples, we can
map the reads from each sample to these contigs. This will result in a matrix of counts of
matches; this can be analyzed and visualized as before with heatmaps, ordinations, and
clustering methods. We refer to these contigs as “putative full or partial viral genomes”. In most
cases, they do not have taxonomic annotations, but we can almost always predict open reading
frames (ORFs) in the genomes (26, 27).
Culture-independent sequencing technology has allowed us to profile the bacterial,
fungal, archaeal, and viral communities within healthy individuals and patients with different
diseases. New tools need to be developed to help us continue our shift from characterization to
testing hypotheses and finding causal links between the microbiome and disease. In the next
section, I describe microbiome therapeutic development, in the form of fecal microbiota
transplants, for several disorders in the clinical trials stage.

Translating Microbiome Science into the Clinic
Fecal microbiota transplantation (FMT) is the infusion of a fecal suspension from a
healthy individual into the gastrointestinal tract of a sick person. This procedure is thought to
restore a healthy, diverse microbial gut community and treat diseases with altered commensal
bacterial communities. FMTs are best known for their high efficacy in the treatment of recurrent

Clostridium difficile infections but have shown promise for many other disorders including
antibiotic-associated diarrhea, inflammatory bowel diseases, irritable bowel syndrome, metabolic
syndrome, autoimmune diseases, allergic diseases, pulmonary-intestinal-associated
inflammatory diseases, and genitourinary tract-intestinal-associated inflammatory diseases (28).
Up until recently, FMTs were exclusively performed through enemas, nasogastric tubes,
4

colonoscopy, endoscopy, or sigmoidoscopy. Industry has now developed orally-administrable
capsules filled with fecal suspension or freeze-dried preparations, to allow more convenient
delivery for patients (29, 30).
History of FMT
th

Literary evidence for FMTs dates back to 4 century China. Ge Hong, a traditional
Chinese medical doctor, described positive results from the use of human fecal suspension by
th

mouth for patients who had food poisoning or severe diarrhea (29, 31). In 16 century China, Li
Shizhen describes using fermented fecal solution, fresh fecal suspension, dry feces, and infant
th

feces to treat severe diarrhea, fever, pain, vomiting, and constipation (32). A 17 century Swedish
text also describes veterinarians transplanting microorganisms from healthy to sick animals (33,
34). Since the 1950s, FMT have been used in the United States sporadically without much
regulation (35-37). Since the early 2010s, interest in FMTs has dramatically increased with many
studies assessing its efficacy for a wide variety of diseases (38); this has resulted in several FDA
regulation and enforcement policies surrounding FMTs.
FMT and C. difficile
The first rigorous randomized controlled trial utilizing FMTs was published in January
2013 and showed 93.8% efficacy rate for FMTs to treat recurring C. difficile infections (37). The
spore-forming C. difficile bacterium becomes more abundant after long-term, continued use of
antibiotics. C. difficile produces toxins which cause the patient to suffer from diarrhea and colonic
disease, and can lead to death (39). Restoring a person’s microbiome with diverse
microorganisms through an FMT provides an environment where other bacteria can better
outcompete C. difficile, effectively reducing it back to healthy levels (40).
IBS and IBD

5

Given the immense success of FMT for treating C. difficile, FMT have been investigated
for several other diseases including refractory diarrhea-dominant irritable bowel syndrome (41,
42) and Inflammatory Bowel Diseases (IBD). IBD is a chronic relapsing inflammatory disorder of
the intestine and includes both Ulcerative Colitis (UC) and Crohn’s Disease (CD). Many studies
have implicated the intestinal microbiota in the pathophysiology of IBD, suggesting that bacterial
dysbiosis in a susceptible host may lead to inflammation through a complex interplay of factors
(40, 43-45). Since mouse models have shown bacteria can activate T-regulatory cells and directly
contribute to the reduction in inflammation (45-48), it is thought that FMT can be used for IBD to
modulate the gut microbiome and improve the existing pathologic inflammatory state. Studies for
FMT and IBD have had mixed results (49). Large scale, phase 3 clinical trials are currently
underway for both CD and UC (50, 51).
Obesity, Type 2 Diabetes, and Non-Alcoholic Liver Disease
Multiple descriptive analyses have suggested an association between obesity and the gut
microbial community in both human and rodent models (52-57). Along with early work showing
that cecal content transplants could alter adiposity in murine models (52), the seminal contribution
to this area came from Jeff Gordon’s lab where colonization of germ-free mice with a stool from
obese mice resulted in greater increase in total body fat than colonization with stool from lean
mice (54, 57). Follow-up to this work has further shown causal links between the microbiome and
obesity and have highlighted the potential contribution of microbiome-modulated immune
responses to the development of obesity and its associated complications in both rodent models
and large-scale human studies (53, 58-65).
Non-alcoholic fatty liver disease (NAFLD), one of the most common causes of chronic
liver disease worldwide (66), is a known co-morbidity of obesity and type 2 diabetes mellitus
(T2D) (67). Small intestinal bacterial overgrowths of Gram-negative organisms have been shown
to promote insulin resistance, increase endogenous ethanol production and induce choline
deficiency, all factors implicated in obesity, T2D, and NAFLD (68). Several clinical trials are
6

currently underway where subjects receive FMT, via capsules or nasoduodenal tube, from lean,
metabolically healthy donors, and the resulting effects on body weight, insulin sensitivity, and/or
amount of fat in the liver are studied (69-71). Given FMT’s success in treating refractory C.
difficile infections, clinical trials are currently underway to investigate FMTs’ efficacy in treating
patients with IBD, IBS, obesity, type 2 diabetes, and NAFLD.

Thesis Outline
Sequencing has greatly increased our ability to query entire communities of microbial
DNA in any part of the human body and investigate how they change with different diseases. In
the first part of this thesis, I investigate the bacteria, archaea and fungi in healthy children and
children with IBD using next-generation sequencing technology. I assess overall diversity and use
the abundance of the microorganisms to predict healthy versus IBD. I also investigate
correlations between the microorganisms. This was all done to better understand the relationship
between the fungi and bacteria in the context of IBD.
In the second part of this thesis, I deploy novel computational methods to investigate
DNA viruses within the respiratory tract. Metagenomic analysis of allograft bronchoalveolar
lavage from lung-transplant recipients was compared to healthy and HIV+ subjects. The viral
communities were compared to the bacterial members and the patient metadata.
Chapters 4 and 5 describe the use of rodent models to assess the efficacy of engineered
microbial communities in reducing long-term production of ammonia and mitigating
hyperammonemia-associated neurotoxicity and encephalopathy. In the intestine, bacterial urease
converts host-derived urea to ammonia and carbon dioxide; thus, we investigated durability of an
engineered community lacking urease capabilities, both in mice on a normal protein diet or a low
protein diet, and the long-term effects the new community had on fecal ammonia levels, mortality,
and neurobehavioral deficits in acute and chronic liver injury models.
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In the last part of thesis, I ask an important question concerning viral transfer during FMT.
Using a sample set of 3 subjects who each received between 22 and 30 FMTs, I search for
viruses present in the donor but not in any of the recipients’ pre-FMT samples. I further develop
the viral analysis pipeline discussed in Chapter 3 and investigate similarity between viruses
transferred to assess if certain viral families or viral genes make viruses more likely to transfer.
This work is important when assessing the safety of FMT, in particular given its increased use.
Overall, I leveraged recent advances in next-generation sequencing technology to
conduct metagenomic analyses of microorganisms in several different diseases. I discuss the
characterization of these microorganisms and how these microorganisms can be modulated to
alleviate disease. I end by describing the viral communities that may play a role in modulating
human gut bacterial communities.
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CHAPTER 2: Fungal Signature in the Gut Microbiota of Pediatric Patients with
Inflammatory Bowel Disease
The contents of this chapter have been published as:
Chehoud C*, Albenberg L*, Judge C, Hoffmann C, Grunberg S, Bittinger K, Baldassano
R, Lewis J, Bushman F, Wu G. 2015. Fungal Signature in the Gut Microbiota of Pediatric
Patients with IBD. Inflammatory Bowel Diseases Journal (PMID: 26083617).

Abstract
Inflammatory bowel disease (IBD) involves dysregulation of mucosal immunity in response to
environmental factors such as the gut microbiota. The bacterial microbiota is often altered in IBD,
but the connection to disease is not fully clarified, and gut fungi have recently been suggested to
play a role as well. In this study, we compared microbes from all three domains of life--bacteria,
archaea, and eukaryota--in pediatric patients with IBD and healthy controls. A stool sample was
collected from patients with IBD (n=34) or health control subjects (n=90), and bacterial, archaeal,
and fungal communities were characterized by deep sequencing of rRNA gene segments specific
to each domain. IBD patients (Crohn’s disease or ulcerative colitis) had lower bacterial diversity
and distinctive fungal communities. Two lineages annotating as Candida were significantly more
abundant in IBD patients (p = 0.0034 and p=0.00038, respectively) while a lineage annotating as
Cladosporium was more abundant in healthy subjects (p=0.0025). There were no statistically
significant differences in archaea, which were rare in pediatric samples compared to those from
adults. Pediatric IBD is associated with reduced diversity in both fungal and bacterial gut
microbiota. Specific Candida taxa were increased in abundance in the IBD samples. These data
emphasize the potential importance of fungal microbiota signatures as biomarkers of pediatric
IBD, supporting their possible role in disease pathogenesis.
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Introduction
The three domains of life--bacteria, archaea, and eukaryota--are all represented in
human gut communities (1-5). Numerous disorders, both intestinal and systemic, have been
associated with alterations in microbial community structure, termed “dysbiosis” (6-8). The
dysbiotic bacterial microbiota has been extensively characterized for the inflammatory bowel
diseases (IBD) and Clostridium difficile infection, although the composition of the archaea and
eukaryota domains and their interaction with bacteria has not been studied in detail. The
pathogenesis of IBD is associated with an inappropriate and persistent inflammatory response to
the commensal gut microbiota in genetically susceptible individuals. In animal studies, dysbiosis
has been associated with the development of intestinal inflammation (reviewed in (6, 8, 9)). Many
of the genetic risk alleles for IBD involve regulation of innate immune responses that protect the
host from bacterial invasion or that regulate the adaptive immune system (reviewed in (10, 11)).
In Crohn’s disease (CD), the phylum Firmicutes is commonly reduced in proportional abundance
(12-17), notably Faecailbacterium prausnitzii (18-20) and members of the Proteobacteria phylum
such as Enterobacteriaceae (21, 22), including E. coli (7, 17, 23) are commonly increased.
The importance of fungi in the human gut to health or disease is not fully understood (2,
24). Fungi, such as Aspergillus, Histoplasma, and Cryptococcus are known to cause pathogenic
intestinal infections. Fungi are also part of the commensal gut microbiota. Increases in gut
Candida species are hypothesized to cause systemic yeast infections in immunocompromised
patients via translocation through the intestinal barrier (25). Fungal-bacterial interactions are just
beginning to be described (1, 5, 6, 26-28), and this may be important in IBD (2).
Several lines of evidence link fungi and IBD. Innate immune receptor activation by fungi
may augment the development of colitis. The main pattern recognition receptors for fungi include
Dectin-1, Dectin-2, DC-SIGN, mannose receptor, and mannose-binding lectin (29). Dectin-1 is a
C-type lectin receptor, which recognizes β-glucans in the fungal cell wall. A recent study (30)
demonstrated that mice lacking Dectin-1 had increased susceptibility to chemically induced colitis
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due to their altered responses to indigenous fungi. A polymorphism in the gene encoding Dectin-1
(CLEC7A) was subsequently associated with a severe form of ulcerative colitis (UC) in humans
(30). There may also be a relationship between high dietary concentrations of yeast and
increased disease activity in patients with CD (31). Treatment with fluconazole, an antifungal,
may reduce inflammation in animal models of colitis and in patients with IBD (32), and elevated
levels of Saccharomyces cerevisiae antibodies are a biomarker for CD (33). Finally, preliminary
studies using denaturing gradient gel electrophoresis (DGGE) suggest that there may be
alterations in gut fungal populations associated with IBD (25, 34).
Alterations in the archaeal microbiota may also be relevent to IBD. Methane production
from archaea has been shown to be altered in patients with IBD (35). Additionally, the syntrophic
interaction between archaea and fermentative bacteria leading to the increase in short chain fatty
acid (SCFA) production (36) may have an impact on mucosal immunity via to the impact of SCFA
on T regulatory cells and immune tolerance (37). Studies of a modest number of subjects are
beginning to suggest that fungi may be dysbiotic in IBD (34) as well as bacteria.
In this study, we use deep sequencing of rRNA gene tags to characterize the composition
of the bacterial, fungal, and archaeal microbiota in pediatric patients with IBD (n=32) and healthy
controls (n=90), revealing a distinctive signature in the mycobiome.

Results
Patient cohort studied
The bacterial component of the microbiome has been studied extensively in IBD, and is
known to be dysbiotic (6, 8, 9, 46). Thus, in this study, we sought to assess effects on the fungal
and archaeal components of the microbiome. A cross-sectional analysis was performed whereby
a single stool sample was obtained from pediatric patients (3 to 21 years of age) with CD, UC, or
indeterminate colitis (IC) (n=32). The diagnosis of IBD was based on endoscopic, radiologic,
laboratory, and clinical findings. Clinical phenotypes of all patients and their therapies are
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described in Supplemental Table 1. Microbiome sequencing results for IBD patients were
compared to results for healthy pediatric and adult subjects studied previously (n=90) (40).
Reduced richness in the intestinal bacterial microbiota of patients with IBD
We first characterized the bacterial composition of the microbiota by purifying and
amplifying DNA using PCR primers recognizing the V1V2 region of the16S rRNA gene, and
pyrosequencing an average of 2,864 reads per sample. We analyzed fecal samples from two IC,
four UC, and 26 CD patients (Sup. Table 2.1). Reads were clustered into operational taxonomic
units (OTUs) at 97% sequence identity, and representative sequences were aligned to databases
for taxonomic attribution. Comparison of data among the disease classes revealed few
differences among groups (Sup. Figure 2.1). Most samples were dominated with Bacteroides. A
few had Clostridia as the dominant taxa.
We compared a dataset from healthy adults and children to the IBD samples (40). OTU
composition was compared in a pairwise fashion between samples using UniFrac, and healthy
and IBD sample sets were compared to each other using PERMANOVA. We observed a clear
separation between the IBD and healthy sample sets (p<0.0001) (Sup. Figure 2.2).
We also investigated the diversity of the IBD samples and healthy controls, since
previously several studies have reported lower diversity in IBD (15). We assessed diversity by
calculating the Shannon Index for each sample, and found that the IBD samples had significantly
lower diversity compared to either healthy adult or pediatric control subjects (p-value <0.05) (Sup.
Figure 2.3).
Comparison of archaea in patients with IBD and healthy controls
We compared the archaeal microbiota composition in the 32 IBD samples with 90 healthy
controls by amplification with PCR primers selective for archaea, then pyrosequencing and
alignment to databases. Only three IBD samples contained detectable Methanobrevibacter (Sup.
Figure 2.4), the major archaeal lineage in healthy adults (5). Six samples had a few reads (<5
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reads each) mostly matching "Unclassified Archaea". Querying those reads against NCBI’s
nucleotide database did not provide clearer taxonomic resolution. We validated these findings by
quantitative PCR targeting Archaea, which confirmed that only three IBD samples,
Subject004_CD, Subject006_CD, and Subject037_CD, had detectable archaea. There was a
lower recovery of archaeal sequences from pediatric IBD samples compared to healthy adults
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(p<1X10 ), but pediatric IBD patients were not significantly different from healthy children
(p=0.128) (Sup. Figure 2.5). This indicates that children have lower archaeal colonization than do
adults, and that alterations in the archaeal colonization of the gut are not related to IBD.
A distinctive fungal signature in the microbiota of pediatric patients with IBD
The fungal representation in the fecal samples was characterized by amplification of stool
DNA with PCR primers targeting the fungal rRNA ITS region, followed by pyrosequencing using
the 454/Roche platform, formation into OTUs at 95% sequence identity, and alignment to
databases. The ITS amplicon has been reported to have biases in recovery of certain lineages
(47), but it does successfully capture a broad range of taxa (5, 26, 28). Thirty-two IBD subjects
were compared to 90 healthy adults and children (40). IBD samples had significantly lower fungal
diversity than healthy children (p-value <0.05) (Figure 2.1).
Ordination analysis based on the presence or absence of fungal species revealed a
separation between healthy and IBD pediatric subjects (p=0.004) (Figure 2.2). Samples from
healthy adults overlapped with both pediatric groups (data not shown). Ordination based on the
abundance (rather than presence/absence) of each fungal species also showed separation
between healthy and IBD pediatric subjects (p=0.044) (Sup. Figure 2.6). A focused analysis of
CD only, in which the IC and UC patients were excluded, also revealed significant separation
between healthy and IBD pediatric subjects (Sup. Figure 2.7 p< .0001).
Next, we investigated whether fungal representation differed in IBD and healthy control
samples (Sup. Figure 2.3). The most commonly observed order was Saccharomyetales, which
contains the genus Candida. IBD samples averaged 2,675 Candida sequences (proportionally
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72.9%) while healthy controls averaged 1,320 reads (proportionally 32.9%) (p=0.0107 based on
read counts). Healthy adults had slightly higher, non-significant average proportions of Candida
than did pediatric healthy subjects (1428 reads (37%) vs. 1055 reads (23%); p=0.535 based on
read counts).
The Candida reads were categorized in 97 different OTUs with the majority belonging to
one OTU (genbank ID: KP132001) (Figure 2.4A). This OTU annotates as single species, which
has previously been given multiple different names, including Pichia jadinii, Candida utilis,
Cyberlindnera jadinii, Torula yeast, and Candida guilliermondii var. nitratophila. This OTU was
significantly enriched in pediatric IBD patients (p-value<0.01 using raw reads or proportion for
both pediatric IBD versus all healthy (adult and pediatric) and pediatric IBD versus pediatric
healthy). A second Candida OTU (genbank ID: EF197997), annotating as Candida parapsilosis,
was also more common in the pediatric IBD samples (Figure 2.4B, p-value <0.01 based on
number of reads). A third OTU (genbank ID: KJ596320), annotating as Cladosporium
cladosporioides, was more common in healthy subjects (pediatric or adult healthy versus
pediatric IBD, p-value <0.01 based on number of reads; Figure 2.4C).
A microbial signature for pediatric IBD
Random Forest, a supervised machine-learning algorithm, was used to generate a
classifier capable of sorting IBD and healthy controls based on microbial community composition.
Classifiers were developed comparing pediatric IBD to pediatric healthy (Figure 2.5A), and
pediatric IBD versus pooled adult and pediatric healthy controls (Figure 2.5B). Classifiers were
compared that used bacterial 16S rRNA gene data only, fungal ITS sequence data only, or both.
The models successfully partitioned the pediatric samples by disease status (Figure
2.5A) and partitioned all healthy controls (children and adults) from IBD children (Figure 2.5B).
For pediatric samples, the16S or ITS OTUs used alone showed a median accuracy of 90% and
83% respectively, while the combination of OTUs showed greater than 93% accuracy. The
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bacterial OTUs that could best distinguish IBD patients from healthy controls annotated as
Bacteroides, Parabacteroides, and Faecalibacterium prausnitzii. For fungi, the classifier was
dominated by OTUs annotating as Pichia jadinii/Candida utilis. The full list of distinguishing taxa
is presented in Supplemental Tables 2.3-2.6.
Bacterial and fungal correlations in IBD
Two-sided, Pearson tests were used to measure correlation between bacterial and fungal
OTUs across IBD samples. Of the 128 bacterial OTUs tested, 33 showed FDR-corrected,
significant (p-value <0.05) correlation with at least one fungal OTU (Figure 2.6). The most
commonly found fungal species in IBD subjects, Candida OTU KP132001, did not correlate
strongly with any bacterial species. Many more significant correlations between fungal and
bacterial OTUs were detected in healthy subjects (Sup. Figure 2.8). Evidently fungal and
bacterial species co-vary, but this was not prominently associated with the lineages implicated as
important in IBD in these subjects.

Discussion
Here, we analyzed the composition and diversity of the fungal, bacterial and archaeal
microbiota in pediatric IBD patients compared to healthy controls. In contrast to the many studies
of the bacterial component of the gut microbiota, there is relatively little known about the fungal
and archaeal microbiota and their roles in IBD. Fungi and archaea are known to be normal
components of the gut microbiota (1, 4, 5, 48). In this study, we recovered abundant fungal reads
from both IBD patients and healthy controls. In contrast, archaea were rare in the pediatric
samples. The potential importance of fungi in IBD is well recognized. Antibodies to baker’s yeast
(Saccharomyces cerevisiae), termed ASCA, are detected more frequently in patients with CD
than in healthy controls or in patients with UC (29-69% of patients with CD (33) (49-51)). The
fungal antigen recognized is thought to be phosphopeptidomannan of the Saccharomyces
cerevisiae cell wall (52). ASCA positivity may precede the development of IBD (53), and ASCA
are found more commonly in healthy relatives of patients with CD (54). The difference in ASCA
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prevalence raises the possibility of a differential fungal microbiota in patients with CD versus
healthy individuals, and our data documents such a difference.
Although the ASCA epitope is associated with S. cerevisiae, it is also associated with
Candida albicans (55) and potentially other related yeasts. Candida colonization has been
associated with multiple diseases of the gastrointestinal tract including CD, UC, esophagitis, oral
mucositis, and even gastric ulcers (56). Candida strains colonize gastric ulcers, particularly when
the ulcers are large or perforated (56) and candida esophagitis responds to antifungal therapy
demonstrating the role of Candida colonization in the pathogenesis of inflammatory processes.
Increased colonization with Candida in IBD might be a consequence of mucosal or immune
system alterations as well as the use of antibiotics(28). The health consequences are unknown
but may be adverse.
We found three fungi with differential abundance in IBD patients versus healthy controls.
Fungal phylogeny is in a state of transition, so species level attributions are not fully secure. For
example, until recently, sexual forms (teleomorphs) were commonly placed in separate genera
from asexual forms (anamorphs) of the same fungal organisms (57). We found one Candida
OTU (genbank ID: KP132001) that was more abundant in patients with IBD, which has been
associated with five named species, including Pichia jadinii, Candida utilis, Cyberlindnera jadinii,
Torulopsis utilis, and Torula utilis (58), illustrating the challenges of current fungal taxonomy. A
common name for this group is Torula yeast. In its inactive form, Torula yeast is widely used as a
flavoring which imparts a savory taste to soups, sauces, and snack products (59). Possibly the
pediatric subjects with IBD were eating diets more enriched in Torula yeasts, though there is no
universal diet for patients with IBD, so this seems unlikely. Patients with IBD frequently identify
dietary components that cause increased symptoms and so follow restricted diets when the
disease is active, but most subjects studied here had relatively low disease activity scores and so
were not expected to be on specialized diets. Also, a review of dietary records kept by the
patients in our study did not reveal an obvious bias towards the consumption of foods rich in
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Torula yeast (data not shown). The second explanation is that there is truly increased Torula
yeast colonization in patients with IBD, which at present seems more likely. Members of the
fungal genus Pichia can be pathogens in humans, especially in immunocompromised hosts (60),
Pichia species may also lead to enteritis in animals (61, 62), and pathogenesis by Candida
species is well described. Further study is needed to clarify whether colonization is related to
disease pathogenesis or whether it is a consequence of gut inflammation or immune suppressive
therapy.
We found a second Candida OTU (genbank ID: EF197997) that was more abundant in
patients with IBD, and a Cladosporium cladosporioides OTU (genbank ID: KJ596320) that was
more abundant in healthy controls. All of the IBD patients in our cohort were undergoing various
therapies, so it is not clear whether these taxonomic changes were associated with the IBD itself
or were a consequence of treatment, for example immunosuppression (63). Other Candida
yeasts, in contrast, are used as probiotics (64), raising the possibility that the yeast lineages
present contribute a mixture of positive and negative influences.
Studies in animal models suggest a functional role for fungi in intestinal inflammation.
Mice lacking the Dectin-1 receptor, a pattern recognition receptor known to identify fungi, were
more susceptible to colonic inflammation in a dextran sodium sulfate (DSS) colitis model (30).
Administration of Candida tropicalis resulted in a more severe DSS-induced colitis in this model,
and treatment with fluconazole, an anti-fungal agent, reduced disease(30). Another PRR,
SIGNR3, was recently found to be involved in recognizing fungal commensals. Mice lacking
SIGNR3 also exhibit increased intestinal inflammation upon exposure to DSS (65). Additional
investigation is needed in humans to determine the mechanisms responsible for the observed
alterations in the fungal microbiota in patients with IBD and the role they may play in disease
pathogenesis via pattern recognition receptors.
To probe distinctive lineages in health and disease, and to develop noninvasive
biomarkers, we developed a Random Forest classifier to sort patients with IBD versus healthy
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controls. Using a combination of bacterial and fungal OTUs allowed greater than 93% accuracy
in distinguishing samples. The currently-available biomarkers focus on the evaluation of patients
already diagnosed with IBD such as differentiating CD from UC, differentiating quiescent from
active disease, and predicting disease course (66). Drug levels and anti-drug antibodies are also
used as biomarkers (66). Unfortunately, the biomarkers currently used to evaluate patients with
symptoms of IBD, such as C - reactive protein, erythrocyte sedimentation rate, and fecal
calprotectin, are not specific to IBD. Additionally, methods are needed to establish early
diagnosis of at-risk individuals, such as asymptomatic family members of patients with IBD. It will
be useful to evaluate the performance of the assay targeting both bacteria and fungi described
here in these settings.
In a recently described analysis of the archaeal microbiome of healthy human subjects,
about 45% of subjects were found to have archaea present in the stool (5). The vast majority of
sequences annotated as Methanobrevibacter (5). In our study, we found only 3 pediatric patients
with IBD with detectable Methanobrevibacter. The previous literature has been inconsistent, with
some studies reporting increased prevalence of methanogens or decreased methane production
in patients with IBD (67-70) and other studies demonstrating increased methane production in
patients with IBD (71). The low number of pediatric IBD subjects found to have archaeal species
from the stool in our study is consistent with a report of methane production increase with aging
(72). Thus our data suggest that archaeal colonization may be more characteristic of the adult
gut microbiota.
In conclusion, we report that pediatric IBD was associated with decreased fungal diversity
and also altered taxonomic composition. We found an increased proportion of two Candida
OTUs in IBD patients. The fungal microbiota may be important in IBD given the increased
prevalence of ASCA and the more recent work suggesting a relationship between fungal pattern
recognition receptors and IBD in mice. We also report a compositional signature elucidated in the
Random Forrest analysis that may be useful in diagnosing IBD patients. Thus, these findings 1)
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clarify the existence and nature of fungal dysbiosis in pediatric IBD, 2) pose the question of
whether specific yeast lineages may be more pro-inflammatory or colonize associated with
inflammation, 3) motivate the investigation of fungal blooms in response to treatment of IBD, and
4) provide a signature of dysbiosis in pediatric patients potentially useful in individualized
molecular diagnosis.
Methods
Subjects
All subjects studied were from the Philadelphia area and <21 years of age (Supplemental
Table 1). Subjects provided written consent or, when appropriate, assent. Subjects were
excluded if they had been treated with antibiotics or probiotics within the two weeks prior to
sample collection, if there was presence of an ostomy, or if they had been treated with
supplemental nutrition (TPN, enteral nutritional therapy, or other nutritional supplements)
accounting for more than 50% of the total caloric intake for the one week prior to sample
collection. Pediatric Crohn’s Disease Activity Index (PCDAI) (38) or Pediatric Ulcerative Colitis
Activity Index (PUCAI) (39) were calculated as described. Stool samples were collected between
February and September 2012 and kept frozen at -80° C until they were processed for DNA
extraction. The sequence samples obtained from the healthy pediatric and adult subjects and
used as controls are described in (5, 40). Briefly, healthy volunteers were screened to be free
from any chronic disease, to have a normal bowel movement frequency, and to have a body
2

mass index (BMI) between 18.5 and 35 kg/m . One stool sample was provided per subject and
kept frozen at -80° C until processed for DNA extraction.
DNA isolation
DNA was isolated from approximately 200 mg of stool using the PSP Spin Stool DNA
Plus Kit (Cat #10381102, Invitek, Berlin, Germany) as per the manufacturer’s instructions.
16S rDNA gene and ITS1 region gene sequencing
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Isolated DNA was quantified using the Picogreen system and 50 ng of DNA was
amplified in each PCR reaction. Primers were barcoded to label each sample as described
previously (41, 42). PCR reactions were carried out in triplicate using Accuprime (Invitrogen,
Carlsbad, CA, USA). Each reaction contained 50 nanograms of DNA and 10 pM of each primer.
Primers annealing to the V1V2 region of the 16S bacterial gene were used for amplification. The
PCR protocol for 16S amplicons was described previously (43). The development of the archaeal
specific 16S rDNA primers and ITS1 fungal primers and PCR cycling conditions are described in
[42]. Amplified 16S rDNA and ITS1 fragments were purified using a 1:1 volume of Agencourt
AmPure XP beads (Beckman-Colter, Brea, CA, USA). The purified products from the stool
samples were pooled in equal amounts and analyzed by pyrosequencing using the Roche/454
Genome Sequencer Junior. DNA pools were separated by amplicon type. DNA-free water was
subjected to the same amplification and purification procedure, and no DNA product was
observed in agarose gels. Sequences of oligonucleotides used in this study are in Supplemental
Table 2.
Sequence Analysis
Sequence data was processed using QIIME (44), augmented by the R package QIIMER
(http://cran.r-project.org/web/packages/qiimer). Taxonomy was assigned to the sequences using
Ribosomal Database Project (RDP) for 16S (45) and the UNITE database for ITS. Further
information on methods can be found in the Supplemental Information.
We fit a Random Forest model to predict health versus disease (IBD) using 16S bacterial
OTUs, ITS fungal OTUs, or a combination of the two. One thousand bootstrapped iterations were
performed to obtain an estimate of the misclassification rate. The classification error rate was
compared to guessing, e.g. if the dataset consisted of 32 subjects with IBD and 68 healthy
subjects, a sample would be randomly classified as a sample from a subject with IBD 32% of the
time and as a sample from a healthy subject 68% of the time.
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Bacterial OTUs with greater than 100 sequences across all IBD samples (128 OTUs)
were correlated with ITS fungal OTUs with greater than 100 sequences across all IBD samples
(27 OTUs). P-values were calculated using a two-sided Pearson correlation test. Bacterial OTUs
with at least one correlation to a fungal OTU producing a Bonferroni-corrected p-value less than
0.05 were displayed on the final heatmap.
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Figures
Figure 2.1. Diversity of fungal communities is decreased in IBD patients compared to
healthy subjects. The Shannon diversity index was calculated based on the OTU-level
classification tables. The boxplots show the distribution of diversity values for: (1) all healthy
subjects, (2) only the adult healthy subjects, (3) only the pediatric healthy subjects, and (4) the
pediatric IBD subjects. Each black dot represents a different subject. *** p<0.0005 on Wilcox
test.
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Figure 2.2. Comparison of pediatric healthy and pediatric IBD subjects’ fungal community
composition using principal coordinate ordination. Principal coordinate analysis was used to
depict the relatedness of fungal communities based on presence or absence. The axes
represent the two most discriminating axes using the binary Jaccard index distance metric.
Pediatric healthy subjects are depicted in cyan and pediatric IBD subjects are depicted in
lavender. The two groups clustered separately (p=0.004).
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Figure 2.3. Taxonomic heatmap of fungal community members in healthy and IBD
subjects. Proportions of fungal OTUs in adult healthy, pediatric healthy, and IBD subjects. The
color bar on the top indicates the health status of each subject. Each column indicates a different
subject. The color bar on the right side indicates the average relative abundances of these
genera in each subject.
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Figure 2.4. Abundance of selected fungal OTUs. Barcharts showing the number of reads from
three selected fungal OTUs: (A) Candida (accession KP132001), (B) Candida (accession
EF197997) and (C) Cladosporium (accession KJ596320). Adult healthy subjects, pediatric
healthy subjects, and pediatric IBD subjects are shown in red, blue, and purple respectively. A
negative control sample (NC) that was processed alongside the samples is shown at the right in
green. No reads matching any of the three lineages mentioned above were found in the negative
control sample.
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Figure 2.5. Random Forest Classification Accuracy for Healthy and IBD subjects. A random
forest classifier was used to group samples into either healthy or IBD categories. Random forest
accuracy (red) was compared to random guessing (blue) with misclassification rate indicated on
the y-axis. The classifier was run using 16S bacterial OTUs, ITS fungal OTUs and the
combination of both bacterial and fungal OTUs. Results were also compared using (A) pediatric
healthy and pediatric IBD subjects or (B) both adult and pediatric healthy subjects and IBD
subjects.
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Figure 2.6. Correlations between Bacterial and Fungal OTUs in pediatric IBD. The Pearson
correlation coefficient between fungal and bacterial OTUs in pediatric IBD patients was
calculated. OTUs were included in this heatmap if they had greater than 100 sequences in
pediatric IBD patients. OTUs were included if they significantly correlated with at least one other
OTU (two-sided correlation, where the p-value exceeded 0.05 after Bonferroni correction).
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Supplemental Information
Supplemental Methods
Sequence analysis
Sequence data was processed using QIIME [1]. Sequences were quality trimmed and
assigned to their respective sample based on their barcodes. Sequences were binned into de
novo Operational Taxonomic Units (OTUs) using CDHIT [2]. with a 97% minimum sequence
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identity threshold for 16S and a 95.2% minimum sequence identity threshold for ITS. The most
abundant sequence from each OTU was selected as the representative sequence for that OTU.
For the ITS analysis, spacer sequences of lengths 130 to 1000 nt were used for the
analysis. In a previous study [3], a longer minimum was used, which resulted in loss of the
unusually short Cyberlindnera jadinii (aka Pichia jadinii and Candida utilis), which is only 142 nt in
length. We also note that length variation in the ITS region may have resulted in underestimation of the abundance of Saccharomyces cerevisiae, which has a relatively long ITS region
(368 nt).
Taxonomy was assigned to the representative sequences using Ribosomal Database
Project (RDP) for 16S [4] and the UNITE database for the ITS. The bacterial sequences were
then NAST aligned using the Greengenes' reference database [5] and used to build a
phylogenetic tree using the using the FastTree algorithm [6]. Bacterial community distances were
calculated between all pair of samples using Unifrac [7]. UniFrac distances are based on the
fraction of branch length shared in a phylogenetic tree between two samples’ microbial
communities. Weighted UniFrac incorporate the relative abundances of each OTU [8]. For the
fungal community distances, Jaccard and abundance-weighted Jaccard indices were calculated.
Principal Coordinate Analysis (PCoA) based on UniFrac distances was used to compare
samples. Heatmaps that show the taxonomic distribution of each sample’s sequences were
created using Qiimer (http://cran.r-project.org/web/packages/qiimer). Diversity was assessed
using the Shannon diversity metric. LEFSE [9] was used to identify taxa that differed between IBD
and healthy samples.
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CHAPTER 3: Blooms of Anelloviruses in the Respiratory Tract of Lung Transplant
Recipients
The contents of this chapter have been published as:
Young J, Chehoud C, Bittinger K, Bailey A, Diamond J, Cantu E, Haas A, Abbas A, Frye
L, Christie J, Bushman F, Collman R. 2014. Blooms of Anelloviruses in the Respiratory
Tract of Lung Transplant Recipients. American Journal of Transplantation (PMID:
25403800).

Abstract
Few studies have examined the lung virome in health and disease. Outcomes of lung
transplantation are known to be influenced by several recognized respiratory viruses, but global
understanding of the virome of the transplanted lung is incomplete. To define the DNA virome
within the respiratory tract following lung transplantation we carried out metagenomic analysis of
allograft bronchoalveolar lavage (BAL), and compared to healthy and HIV+ subjects. Viral
concentrates were purified from BAL and analyzed by shotgun DNA sequencing. All of the BAL
samples contained reads mapping to anelloviruses, with high proportions in lung transplant
samples. Anellovirus populations in transplant recipients were complex, with multiple concurrent
variants. Q-PCR quantification revealed that anellovirus sequences were 56-fold more abundant
in BAL from lung transplant recipients compared with healthy controls or HIV+ subjects
(p<0.0001). Anellovirus sequences were also more abundant in upper respiratory tract specimens
from lung transplant recipients than controls (p=0.006). Comparison to metagenomic data on
bacterial populations showed that high anellovirus loads correlated with dysbiotic bacterial
communities in allograft BAL (p=0.00816). Thus the respiratory tracts of lung transplant recipients
contain high levels and complex populations of anelloviruses, warranting studies of anellovirus
lung infection and transplant outcome.
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Introduction
Little is known about the virome of the human respiratory tract as a whole, though
infections by individual viruses are well characterized. For the case of lung transplantation, viral
infection is a major complicating factor impacting graft survival rates (1-4). Respiratory infections
with known viruses can cause direct lung injury or increase risk of graft failure, as in the case of
cytomegalovirus and community acquired respiratory viruses (1, 5). Intense interest has thus
focused on viruses in the respiratory tract and transplantation outcome.
Today it is possible to characterize large viral populations using high throughput
metagenomic sequencing (6-8), which has identified both well-recognized and little-studied
viruses living in association with humans. Only a few studies have applied metagenomic
approaches to understand viruses of the lower respiratory tract (8, 9), and none in lung
transplantation.
Anelloviruses are circular, nonenveloped, negative-sense, single-stranded DNA viruses
that commonly colonize humans and show increased abundance in blood after hematopoietic and
solid organ transplantation (10-12). The anellovirus family consists of Torque Teno viruses
(TTVs), Torque Teno Midi Viruses (TTMDV), Torque Teno Mini Viruses (TTMV), and Small
Anelloviruses (SAVs), each of which has multiple subtypes (12, 13). Their small genomes (2.33.8 kb) consist of three to four open reading frames and a highly conserved untranslated region
(UTR) (12)_ENREF_8. These viruses are ubiquitous in the human population and have not yet
been causally linked with any human disease (12, 13). Diverse types of anelloviruses have been
found in various organs, tissues, and cell types (12, 14-16).
In the respiratory tract, TTV was recently identified in bronchoalveolar lavage fluid from
28% of individuals with acute exacerbations of idiopathic pulmonary fibrosis (IPF), but not those
with stable IPF, and in a quarter of individuals with acute lung injury (17). In the upper respiratory
tract, elevated levels of TTV have been found in nasal secretions from children with respiratory
diseases, and correlated with disease severity (15, 16). In HIV-infected patients, plasma
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concentrations of anelloviruses increased during progression to AIDS (18) and decreased
following therapy (19). TTV viremia was reported to increase following autologous hematopoietic
stem cell transplantation, and then return to baseline levels following immune reconstitution (10).
Recently, TTV levels in blood were shown to increase in association with immunosuppression
following lung and heart transplantation (11). The association between TTV levels and immune
status has led some authors to propose that anelloviruses genome copy numbers may serve as
an empirical measure of successful immune suppression (10, 11, 19).
We report here the first study to apply viral metagenomics to understand the lung virome
in lung transplantation. We first used Illumina metagenomic sequencing to characterize lung DNA
viromes from lung transplant recipients, along with another immunologically impaired group, HIVpositive individuals. This showed that anellovirus sequences were prominent in BAL from
transplant recipients, and revealed the presence of complex populations with multiple concurrent
variants. Based on these metagenomic data, we then quantified anellovirus levels within the
lungs and upper respiratory tracts of lung transplant recipients, HIV+ subjects, and healthy
individuals using Q-PCR, demonstrating high levels of anellovirus DNA in BAL and OW of lung
transplant recipients. Our findings demonstrate metagenomic detection and genetic
characterization of the allograft virome, which is then followed by broader quantitative analysis.
We also compared metagenomic data on bacterial populations, and found that high levels of
anelloviruses correlated with dysbiotic bacterial communities, revealing covariation among
microbiome constituents.

Results
BAL and OW samples were collected from 1) lung transplant recipients undergoing posttransplant bronchoscopy, 2) HIV+ individuals without lung disease or respiratory symptoms, and
3) healthy control subjects (20, 21) (Sup. Tables 3.1, 3.2, and 3.3). VLPs were purified from BAL
and OW, followed by concentration and treatment with nucleases to eliminate non-encapsidated
nucleic acids (Figure 3.1). DNA was then purified from each sample. To verify selective reduction
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in human and bacterial cells, two BAL samples were analyzed using Q-PCR to quantify bacterial
16S rRNA gene copies or human beta-tubulin gene copies. Copies of bacterial 16S DNA
decreased from 3000 copies/ng in unfractionated BAL to 80 copies/ng after viral particle
purification (38-fold reduction). Human beta-tubulin DNA was detected at 925 copies/ng in
unfractionated BAL but became undetectable after purification (>900-fold reduction).
Metagenomic sequencing of lung transplant and HIV+ samples
We first applied metagenomic analysis to viral DNA from six lung transplant and three
HIV+ BAL samples. DNA from viral preps was subjected to whole genome amplification and then
shotgun sequenced using the Illumina MiSeq platform (2 x 250 bp reads) (Table 3.1). Up to 3.4
9

million reads per sample were generated, for a total of 5.42x10 bp of sequence data. Reads
were filtered and trimmed to remove low quality sequences, and human reads were identified and
removed. Reads were then aligned using BLAST to the NCBI viral database (Table 3.1 and Sup.
Table 3.4).
Of reads assigned to reference viruses, the majority (>68%) mapped to anelloviruses,
which included Torque Teno viruses, Torque Teno Mini viruses, Torque Teno Midi viruses, and
Small Anelloviruses (Table 3.1, Figure 3.2A). Based on the closest match to reference viruses, a
wide variety of anelloviruses were present within the lungs of lung transplant subjects, while
substantially fewer anellovirus reads were detected in lungs of HIV+ individuals (Figure 3.2A).
Furthermore, diverse anelloviruses were present in single individuals, especially in the lung
transplant recipients, as evidenced by reads aligning to many different TTVs, TTMVs, TTMVDs,
and SAVs within single samples (Table 3.1).
Other eukaryotic viruses were detected within the samples, but at much lower levels.
These included Epstein-Barr virus (Human Herpesvirus 4) (2 reads in one sample), Human
Herpesvirus 7 (2 reads in one sample, 36 reads in another sample), and Human Papillomavirus
(1 read) (Sup. Table 3.4). To determine whether use of the 0.22 micron filter step during virus
40

purification may have resulted in depletion of some of the larger viruses, we compared filtration
and centrifugation (Sup. Table 3.6). This showed that filtration resulted in reduced recovery of
herpesviruses, but was more efficient at capturing small viruses such as human papillomaviruses
and anelloviruses.
A small percentage of reads (0.75% of total reads for all samples combined) aligned to
bacteriophage genomes, predominantly phages of Enterobacteria, Salmonella, Pseudomonas,
Streptococcus and Yersinia. When bacterophages were compared with bacterial 16S sequences
from these subjects that were previously analyzed (31), we found representation of several of
these bacterial lineages (Streptococcus, Pseudomonas, Staphylococcus, and Enterobacteria),
consistent with possible phage/host pairs in our samples.
An average of 81% of the reads did not match reference viruses in the NCBI viral
database, a high proportion similar to results of other viral metagenomic studies (9, 32). We
surmise that many of these may correspond to DNA phage sequences, because phage are
hyperabundant globally and poorly represented in sequence databases (33). Unidentified reads
could also correspond to novel mammalian viruses or low quality reads not removed by our
filtering strategy.
Genetic structure of lung anellovirus populations
Anellovirus reads were assembled into contigs for more complete analysis of
anelloviruses community structure, using iterative deBruijn graph assembly (23). To validate
correct contig assembly, we designed specific primer sets for three of the contigs, then PCR
amplified 500-700 base pair regions, sequenced using the Sanger method, and assembled using
the conventional overlap method. Assembled contigs were then aligned to the NCBI nt database
(Figure 3.2B). Selected regions within the anellovirus contigs were 87-93% identical to the
reference sequences, though highly divergent regions were also detected. Anellovirus open
reading frames (ORF) 1 and 2 were identified in the three anellovirus contigs. ORF1 was
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previously shown to encode the capsid gene and contains a hypervariable region, which may
evolve rapidly to evade the host immune response (12). The ORF2 encoded protein was reported
to suppress the NF-kB pathway, thereby potentially regulating the host innate and adaptive
immune response (12, 34).
To compare anelloviruses populations within and between individuals, a phylogenetic
tree was generated using ORF1 sequences from reference genomes and contigs assembled
from the Illumina and Sanger sequence data. As shown in Figure 3.3, multiple different
anellovirus ORF1s were found within individual lung transplant patient allografts, with subjects
exhibiting as many as 17 distinct contigs. In contrast, richness of anelloviruses was lower in BAL
of HIV+ individuals, even though sequences were detected in all of them. Anellovirus contigs
were mostly different between individuals (Figure 3.3).
Quantification of Anellovirus DNA in lung and upper respiratory tract samples using quantitative
PCR
Given diverse anellovirus populations found in some of the transplant samples, we
sought to quantify absolute anellovirus DNA levels in a larger group of subjects using Q-PCR.
We used the universal PCR primers targeting the anellovirus highly conserved UTR (22) to
generate a Q-PCR assay. These primers recognize TTVs, TTMVs, TTMVDs, and SAVs. We
analyzed a total of 53 BAL samples from lung transplant recipients (n=38), HIV+ subjects (n=3),
and healthy controls (n=12). To assess the upper respiratory tract, we also analyzed 24 OW
samples from lung transplant recipients (n=12) and healthy controls (n=12).
As shown in Figure 3.4, anellovirus copy numbers in lung ranged widely among
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transplant recipients, with a median of 15,133 copies/ml (range=314 to 2.3x10 copies/ml). These
levels were far higher than in lungs of healthy or HIV+ subjects (medians of 271 and 191
copies/ml, respectively; p<0.0002 for comparison to lung transplant samples; Mann-Whitney test).
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Quantities of anelloviruses in the upper respiratory tract were also measured in OW
collected from lung transplant recipients and healthy subjects. As was seen in lung, anellovirus
genome copies were significantly more abundant in the upper respiratory tract of transplant
recipients compared with healthy controls (Figure 3.5) (median=16,700 in transplant recipients,
range=634 to 632,759 copies/ml compared to median=1,033 in healthy; p=0.0055). When
quantities of anellovirus were compared between lung and upper respiratory tract within the same
treatment group, healthy subjects had significantly lower titers in their BAL compared to
oropharyngeal wash (p=0.0068, Mann-Whitney test). However, in lung transplant recipients,
anellovirus genome copies were higher in both sample types and not significantly different in lung
compared to the upper respiratory tract (p=0.23, Figure 3.6).
Comparison of anellovirus DNA levels to transplant subject metadata
We then asked whether anellovirus levels in the transplant recipients’ lungs were
correlated with clinical variables that might explain the high variability. We queried patient age,
gender, time since transplant, number of immunosuppressive drugs, tacrolimus levels,
prednisone dosing, target immunosuppression range, surgical type (single vs. bilateral lung
transplant), use of azithromycin, cytomegalovirus status (donor and recipient), BAL bacterial
culture results and bacterial load in BAL based on 16S rRNA gene Q-PCR, acute rejection grade,
and pre-transplant diagnosis (suppurative vs. nonsuppurative lung disease). No significant
associations were detected (Sup. Table 3.5). Though power was limited by the relatively small
sample sizes, these data suggest that anellovirus replication in the lung allograft is linked to
factors other than these clinical variables.

Comparison of lung anellovirus DNA levels to the bacterial microbiome
Finally, we asked whether there was a relationship between anellovirus DNA levels and
composition of the bacterial microbiome in allografts. Previously, DNA was purified from whole
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BAL, PCR ampified using primers that recognize conserved regions of the bacterial 16S rRNA
gene, and products analyzed by deep sequencing (20). That analysis showed that lung transplant
bacterial communities differed in composition from healthy subjects, and transplant recipients
were commonly colonized by oral bacteria, known pathogenic bacteria, and sometimes by
unexpected bacterial lineages. Absolute levels of bacteria were also higher than in healthy
controls (40-100-fold). Here we compared the anellovirus titers with bacterial community
composition among transplant recipients, and found a significant correlation (Figure 3.7; weighted
UniFrac, p=0.032). However, no specific bacterial lineages were significantly linked to anellovirus
levels among transplant subjects. We then asked if the relationship between anellovirus and 16S
bacterial composition might be linked to the degree to which the bacterial communities diverged
from healthy controls. This analysis revealed a significant correlation between transplant BAL
anellovirus levels and a metric measuring the divergence between the corresponding bacterial
community and those of healthy subjects (Sup. Figure 3.1; p=0.008). Thus, high anellovirus levels
in transplant recipients are also associated with aberrant bacterial microbiota.

Discussion
Here we used metagenomic sequencing to analyze DNA viruses present in the
respiratory tract of lung transplant recipients and HIV-infected individuals. The metagenomic data
then enabled targeted analysis of anellovirus levels in a larger cohort of lung transplant and
control subjects. This is the first study to apply viral metagenomics to the lung transplant allograft.
Multiple viruses infecting animal cells were detected by sequencing, including a remarkable
abundance and complexity of anelloviruses, as well as much lower levels of papilloma viruses
and herpes viruses. Bacteriophage were also detectable, as were unidentified sequences likely
corresponding at least in part to phages. Our most notable finding was that the anelloviruses,
including TTVs, TTMVDs, TTMVs, and SAVs, were greatly increased in abundance in the lungs
and the upper respiratory tract of lung transplant recipients compared with healthy and HIV+
subjects. As this work was being completed, Quake and colleagues reported that anellovirus
sequences were increased in abundance in blood in organ transplant recipients (11). Our data
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reported here show that after lung transplantation, anellovirus sequences are abundant in the
lung allograft itself.
The shotgun metagenomic sequence data enabled assembly of near-complete genome
sequences for some of the most abundant anelloviruses, allowing the genetic nature of
anelloviruses present to be analyzed in detail. A notable feature of transplant recipients was the
great diversity of anelloviruses represented within single individuals. Quantifying the exact
number of different forms is challenging and dependent on the metric chosen. Taking each
independent contig into account, there were up to 247 contigs identified as anelloviruses within
one sample (Tx-24). However, this may be an overestimate because some contigs are only
partial genomes (sizes ranged from 250-3600 base pairs), though this is hard to assess
definitively because replication-competent subviral molecules have been reported (35). Analysis
based on viral ORF1 regions showed that up to 17 different anelloviruses were present within a
single transplant recipient (Tx-24), indicating remarkable diversity. Some of the anelloviruses
identified in these subjects were distant in sequence from database genomes. Such high
divergence was confirmed in the three genomes reconstructed by Sanger sequencing, and so is
not a result of error in Illumina sequence determination or assembly. The origin of this extreme
diversity is unclear, but may be due in part to the known high mutation rates of single-stranded
DNA viruses (36) combined with high virus levels likely reflecting high rates of virus replication in
lung.
We found large numbers of bacteriophage sequences in our shotgun metagenomic data,
likely due to the abundant bacterial populations in lung transplant subjects (20), but relatively few
mammalian DNA viruses besides anelloviruses. This is likely in large part related to the nearuniversal use of herpesviruses prophylaxis in transplant subjects, and relatively modest level of
immune dysfunction based on CD4+ T cell counts in our HIV+ subjects. In addition, samples for
metagenomic analysis were subject to multiple displacement amplification, which favors small
circular genomes such as anelloviruses. An additional technical factor may be that the filtration
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step used could have depleted large viruses or viral particles bound to other macromolecules,
although reconstruction experiments suggest that the losses were modest. In addition, a large
proportion of sequences did not match any database genomes, which is concordant with findings
in other metagenomic virome studies (6, 9, 32). While many of these are likely novel
bacterophages, it is possible that novel mammalian viruses may exist within those sequences as
well. One limitation of our sample set is the relatively short elapsed time since transplant (median
of 5 months), and it will be useful to investigate whether additional viral lineages emerge over
longer times.
Anellovirus genome copy numbers in lung from Q-PCR data were remarkably different
among transplant subjects, varying across nearly 5 orders of magnitude. However, comparison
to standard patient metadata did not show significant correlations with any of the clinical
parameters queried. A recent study of anellovirus in serum following organ transplantation
reported that anellovirus genome levels correlated with the extent of immunosuppression,
suggesting that anellovirus DNA in blood might serve as an assay for the overall level of
immunosuppression (11). In contrast, our subjects were receiving relatively homogenous
immunosuppression regimens (Table S1), and we found no association with any measure of
immunosuppression, nor with time since transplant (Table S5). Thus, the absence of correlations
seen here between lung anellovirus levels and clinical variables suggests that anellovirus
replication in lung allografts may be regulated by factors that have yet to be identified.
We compared anellovirus DNA quantification to previously determined data on the
structure of bacterial communities, and identified a novel form of covariation. Among transplant
recipients, BAL samples with high anellovirus levels differed from those with lower levels based
on the bacterial 16S data. Furthermore, samples with highest levels of anellovirus were more
divergent from the bacterial communities of healthy controls, indicating bacterial dysbiosis. This
suggests that the anellovirus and bacterial communities may both be blooming in response to
some common property of the host, such as loss of immune control. If so, the immune impairment
46

would not be reflected by standard clinical measures, which did not correlate with features of
anelloviral DNA levels. The correlation between anellovirus titers and bacterial dysbiosis was
imperfect, however, indicating that there are likely both shared and unique factors influencing viral
and bacterial microbiota, respectively.
In summary, our results employing shotgun metagenomic sequencing revealed robust
anellovirus populations in lungs of lung transplant recipients, which was then confirmed and
quantified by targeted Q-PCR. Long-term lung transplant outcomes have been linked to prior
infection with several other viruses (1, 2, 4). While our subjects were sampled at relatively early
time points (median 5 months post-transplant), early post-transplant colonization with other
microbial agents has been associated with BOS at later time points (37, 38). Thus, the finding of
unexpected high levels of anellovirus replication within lung allografts and marked inter-subject
variability suggest that longitudinal studies are warranted to determine whether levels of
anelloviruses in the lung allograft are associated with, and may play a role in, transplant
outcomes.
Methods
Sample collection
Bronchoalveolar lavage (BAL) was carried out within the lung allograft on lung transplant
recipients, most of whom were undergoing routine clinical surveillance bronchoscopy during the
first year post-transplant (Sup. Table 3.1) as described previously (20). Oropharyngeal wash
(OW) to sample the upper respiratory tract was collected as previously described (20). One group
of control samples were obtained from healthy volunteers who underwent research bronchoscopy
using the same procedure (Sup. Table 3.2). Samples from three HIV+ subjects not on
antiretroviral therapy (CD4 T cell counts of 301, 321 and 682; Sup. Table 3.3) and a second set
from healthy volunteers (Table S2) were obtained by bronchoscopy using a previously described
two-scope procedure (21). The University of Pennsylvania IRB approved all procedures
(protocols # 812748 and #810851), and subjects gave written informed consent.
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Virus-Like Particle (VLP) purification
Virus-like particles were purified from 1-5 milliliters of BAL or OW, depending upon
availability. 10mM MgSO4 and 10mM dithiothreitol were added to the BAL or OW and filtered
through a 0.22 µm filter (Millipore). The filtrate was concentrated using a 100kDa molecular
weight cut-off filter (Amicon 20, Millipore), resuspended in 1 ml Buffer SM_ENREF_21, and
reconcentrated. The concentrate was treated with DNase I and RNase (Roche) at 37°C for 15
min to eliminate non-encapsidated nucleic acids, then the enzymes were deactivated at 70°C for
5 min.
Nucleic acid extraction and metagenomic sequencing
Nucleic acids were extracted from virus particle preps using Qiagen’s All Prep nucleic
acid isolation kit. Six lung transplant and three HIV+ BAL samples that had large volumes of BAL
and detailed patient metadata available were used for metagenomic sequencing. Whole genome
amplification was performed on these samples using the GenomiPhi V2 Amplification Kit (GE
Healthcare). Libraries for sequencing were made using Illumina’s Nextera XT DNA Sample
Preparation Kit with 1 ng of input DNA, generating paired-end fragments. Metagenomic
sequencing was performed on an Illumina MiSeq instrument.
Quantitative PCR
Q-PCR was carried out on non-Genomiphi amplified DNA using primers targeting the
UTR of anelloviruses from a previously-described assay (22) that we adapted to a SYBR greenbased method as described in Supplemental Methods. All samples were run in duplicate or
triplicate and values averaged. The detection limit was 1.4 copies per reaction.
Bioinformatics pipeline
Paired-end reads from the MiSeq instrument were quality-trimmed and processed
through BMTagger to remove human sequences. Non-human reads were then analyzed using
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BLAST against the NCBI viral database. Reads were assembled into contigs by iterative deBruijn
graph assembly using IDBA-UD (23). To verify contig assembly, contig-specific PCR primers
were synthesized and amplification products subjected to Sanger sequencing. Dot plots were
generated using Gepard with a word size of 10 nucleotides (24). Anellovirus ORF1 amino acid
sequences were identified from our contigs and aligned along with 49 reference TTV, TTMDV,
and TTMV sequences from Genbank. The phylogenetic tree was built using FastTree v2.1.3 (25).
Further details of bioinformatic analysis are provided in Supplemental Methods.
Analysis of 16S reads from (20) was undertaken using QIIME v1.8 (26). Operational
taxonomic units were selected at 97% sequence similarity with UCLUST (27). Following this step,
the seed sequences from the clustering algorithm were used as representatives for each cluster.
Taxonomic assignments against the GreenGenes 16S database v13_8 (28) were generated
using the default consensus method in QIIME. A phylogenetic tree was estimated by FastTree
v2.1.3 (25) using PyNAST-aligned representative sequences (29). Pairwise UniFrac distances
were then calculated using the implementation in QIIME.
Statistical analyses
Mann-Whitney tests, paired Wilcoxon signed rank tests, t-tests, and Spearman
correlation tests were performed in R (30).
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Table and Figures
Table 3.1. Anelloviruses identified through metagenomic sequencing of BAL samples from
lung transplant recipients and HIV+ individuals.
Lung Transplant Recipients

HIV+

Total Reads (Unfiltered)
Total Reads after Quality Trimming
% Human Reads
% Reads Matching to Viral DB
Small anellovirus 1
Small anellovirus 2
Torque teno felis virus
Torque teno midi virus 1
Torque teno midi virus 2
Torque teno mini virus 2
Torque teno mini virus 3
Torque teno mini virus 4
Torque teno mini virus 5
Torque teno mini virus 7
Torque teno mini virus 8
Torque teno virus 1
Torque teno virus 10
Torque teno virus 12
Torque teno virus 14
Torque teno virus 15
Torque teno virus 16
Torque teno virus 19
Torque teno virus 2
Torque teno virus 27
Torque teno virus 28
Torque teno virus 3
Torque teno virus 4
Torque teno virus 6
Torque teno virus 7
Torque teno virus 8
Torque teno virus

HUP1A03

HUP1B03

HUP1B07

Tx-24

Tx-34

Tx-38

Tx-49

Tx-51

Tx-52

1,134,270
1,134,256
0%
4%
0
0
0
0
0
0
0
0
0
0
0
4
8
4
1
19
7
7
1
2
3
5
2
19
4
20
0

3,480,764
3,480,750
0%
4%
0
0
0
0
0
0
0
0
0
0
0
6
10
13
4
46
18
12
6
0
3
33
1
24
48
28
1

649,864
649,852
0%
5%
0
0
0
0
0
0
0
0
0
0
0
3
3
0
0
19
5
5
0
1
1
1
0
5
2
79
0

644,536
644,526
1%
21%
1
14
0
20
13
0
0
0
0
5
0
3124
6984
9946
480
44356
10860
3102
262
1381
211
15693
853
22153
8714
6834
1076

869,518
869,504
0%
23%
2
0
0
1
1
4
0
6
0
0
3
10901
10537
222
15
75859
5918
12143
7
1046
80
59
9
13397
28
69854
3

1,236,626
1,236,620
26%
1%
0
0
1
0
0
0
5
0
7
9
2
44
97
21
290
115
166
78
82
46
11
79
0
184
20
868
24

1,169,756
1,169,742
29%
10%
0
0
0
0
0
0
2
0
0
0
0
1051
4828
2695
10819
7173
19424
14768
66
1036
161
19995
1114
10487
1950
17068
970

171,892
171,884
21%
7%
0
0
0
0
0
0
0
0
0
0
0
128
513
98
4235
564
175
233
501
57
6
1202
661
127
22
2440
0

71,018
71,010
14%
1%
0
0
0
0
0
0
0
0
18
6
0
2
1
4
0
3
0
2
0
1
0
0
0
6
0
24
0
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Figure 3.1. Overview of experimental design. BAL and OW samples (1-5 ml) were filtered
through a 0.22 µM filter, concentrated on an Amicon 10 kDa MWCO filter, washed, and treated
with DNase and RNase to yield purified virus-like particles. Select samples were checked for viral
purity by quantifying the bacterial 16S rRNA and human β-tubulin genes using Q-PCR.
Anelloviruses were quantified in all samples by Q-PCR. Select lung transplant and HIV+ samples
were whole-genome amplified by multiple displacement amplification (MDA) and shotgun
sequenced using the Illumina MiSeq platform. Bioinformatic analysis of the virome reads
consisted of removing human reads (BMTagger) and aligning to the NCBI viral database. Reads
were assembled into contigs, aligned to the NCBI viral database and analyzed.
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Figure 3.2. Anelloviruses in BAL of HIV+ individuals and lung transplant recipients. A)
Distribution of reads aligning to anelloviruses. Metagenomic sequencing reads were searched
against the NCBI viral database and the number of combined reads aligning to each anellovirus
calculated for lung transplant recipients (n=6) and HIV+ subjects (n=3). B) Presence of multiple
anelloviruses present within the lungs of lung transplant recipient Tx-24 verified by Sanger
sequencing. For each of the three analyzed by Sanger sequencing (x-axis), similarity was scored
versus their closest matching NCBI reference sequence (y-axis). Open reading frames were
assigned using MacVector and are illustrated on the genetic maps under the dot plots.

A

HIV+

TTV
TTV 1
TTV 2
TTV 3
TTV 4
TTV 6
TTV 7
TTV 8
TTV 10
TTV 12
TTV 14
TTV 15
TTV 16
TTV 19
TTV 27
TTV 28
TTMDV 1
TTMDV 2
TTMV 2
TTMV 3
TTMV 4
TTMV 5
TTMV 7
TTMV 8
TTV felis
SAN1
SAN2

Lung Tx

483 reads

462,944 reads
Tx-24 contig1

3503

TTV15
3786

Tx-24 contig2

0
0

3195

TTV12

0
0

91% identity over
24% of contig

3758

TTV15

ORF 2

87% identity over
100% of contig

600

ORF 2

900

1200

1500

1800

2100

2400

2700

3000

3300

3600

Tx-24 contig1

600

900

1200

1500

1800

SAV5A

ORF 2

300

600

900

1200

1500

1800

2100

2400

2700

3000

3300

3600

300

Tx-24 contig2

ORF 2

2400

2700

3000

3300

300

600

900

1200

1500

ORF 3

ORF 1
600

ORF 2

900

1200

1500

1800

2100

2400

2700

3000

Tx-24 contig11 ORF 3

ORF 1
2100

2807

93% identity over
94% of contig

ORF 1

ORF 1
300

3086

TTV12

ORF 2

ORF 1
300

Tx-24 contig11

0
0

SAV5A

B

ORF 1

1800

2100

52

2400

2700

3000

300

600

900

1200

1500

1800

2100

2400

2700

Figure 3.3. Diversity of anellovirus ORF1 sequences in samples from each individual
studied. ORF1 amino acid sequences from anellovirus contigs and Genbank reference
sequences were aligned and trimmed to generate the phylogenetic tree shown. The names of the
reference sequences include the TTV strain name followed by the Genbank identification (gi)
number. Clades are designated as groups, in the outer ring, as described by Okamoto et al (12,
22). The BAL sample of origin of each ORF1 sequence is designated by the color code (key at
right). The Shimodaira-Hasegawa (SH) score was calculated using FastTree to estimate the
reliability of each split compared to alternate topologies (25). Local SH support values over 0.9
are labeled as circles on the nodes of the tree. The scale bar represents the number of amino
acid substitutions per position.
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Figure 3.4. Abundance of anelloviruses in BAL samples. Anelloviruses were quantified by QPCR in BAL from lung transplant recipients, healthy individuals, and HIV+ individuals. Boxes
represent the middle two quartiles for each group and whiskers are placed at the minimum and
maximum values. Quantities were higher in lung transplant recipients compared with healthy and
HIV+ individuals as determined by the Mann-Whitney test with Bonferroni correction: p<0.0002.
All samples quantified were above the Q-PCR detection limit (1.4 copies per reaction).
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Figure 3.5. Abundance of anelloviruses in OW samples. Anelloviruses were quantified by QPCR in oropharyngeal wash from healthy individuals and lung transplant recipients. Anellovirus
quantities were higher in the upper respiratory tract of lung transplant recipients compared with
healthy individuals. Mann-Whitney test: p=0.0055. All samples quantified were above the Q-PCR
detection limit.
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Figure 3.6. Comparison of anellovirus quantities in lung and upper respiratory tract within
individuals. Paired Wilcoxon signed rank tests were performed on anellovirus copies from BAL
and OW in A) healthy control subjects and B) lung transplant recipients. Anellovirus DNA copies
were lower in the lung compared with the upper respiratory tract of healthy controls but not in lung
transplant recipients (p-values: 0.0068 and 0.23, respectively).
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Figure 3.7. Ordination based on composition of bacterial 16S sequence analysis, showing
the relationship to anellovirus DNA copy numbers. Each circle on the plot shows data for a
single transplant recipient BAL sample. For each sample, bacterial 16S rRNA gene tags were
subject to deep sequencing (median 7,925 reads per sample; data published in (20)) and
analyzed using Weighted UniFrac, which generated a set of pairwise distances among samples.
The distances were then analyzed using Principal Coordinate Analysis (PCoA), and the samples
plotted along the first two principal coordinates. For each sample, the anellovirus titer is
summarized by the size of the open circle. Among these transplant recipient BALs there is a
significant relationship between anellovirus DNA level and 16S bacterial community composition,
which is reflected in the observation that samples with low anellovirus titers tend to appear on the
lower left side of the PCoA plot (p=0.032; ADONIS test).
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Supplemental Information
Supplemental Methods
Quantitative PCR
Q-PCR was carried out on non-Genomiphi amplified DNA isolated from BAL and OW.
TTV primers NG779 (ACWKMCGAATGGCTGAGTTT) and
NG781 (CCCKWGCCCGARTTGCCCCT) targeting the UTR of anelloviruses were used (1), and
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the assay adapted to a quantitative SYBR green-based Q-PCR. Briefly, a 126 bp fragment
from TTV was amplified by end-point PCR, TA-cloned into the pCR4 TOPO vector (Invitrogen),
quantified by PicoGreen, and used to generate a standard curve. 10µl SYBR green FAST master
mix (Applied Biosystems), 50µM of each primer, and 10µl standard curve or DNA (diluted 1:10)
were added per well. PCR cycle parameters were as follows: 95°C for 90 seconds, and forty
cycles of 94°C for 15 seconds, and 68°C for 1 minute. Melt curve analysis of amplification
products showed a single transition suggestive of formation of a single DNA product. All samples
were run in duplicate or triplicate and values averaged. The detection limit was 1.4 copies per
reaction.
Bioinformatics pipeline
Paired-end reads from the MiSeq instrument were quality-trimmed and processed
through BMTagger to remove human sequences. Non-human reads were then analyzed using
BLAST against the NCBI viral database (downloaded April 2, 2013 from
https://www.ncbi.nlm.nih.gov/genomes/Genomes Home.cgi) and the percent of each virus
genome covered by reads was calculated. The percentage of paired reads matching the same
virus was also calculated. Subsequently, reads were aligned to selected individual viruses one at
a time. The alignments were performed using Bowtie2 (2) and visualized using IGV (3). A large
number of reads (170,651 across all samples) showed a best BLAST hit from the NCBI viral
database to a 50 base region within the RNA plant virus Physalis mottle virus. This sequence
covered less than 1% of the genome, and also shared 100% nucleotide identity with DNA cloning
vectors, so those sequences were removed manually from the analysis.
Reads were assembled into contigs by iterative deBruijn graph assembly using IDBA-UD
(4). Sanger sequencing was performed on selected contigs following PCR amplification using
contig-specific primers to verify sequences. Dot plots were generated using Gepard with a word
size of 10 nucleotides (5). Anellovirus ORF1 amino acid sequences were identified from our
contigs and aligned along with 49 reference TTV, TTMDV, and TTMV sequences from Genbank.
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Sequences were aligned using MUSCLE v.3.8.31 (6) and trimmed to include only columns with
80% amino acid coverage. Subsequently, the 10% most variable columns were removed. The
phylogenetic tree was built using FastTree v. 2.1.3 (7) which calculates local support values using
the Shimodaira-Hasegawa (SH) test to estimate the reliability of each split compared to alternate
topologies (7-10). The groups, color bars corresponding to the samples, and SH- indices were
incorporated using iTOL (11). Groups were chosen based on clades determined by SH-indices
(>90%) and a guide tree previously published by Okamoto et al (12).
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Abstract
Increasing evidence indicates that the gut microbiota can be altered to ameliorate or prevent
disease states, and engineering the gut microbiota to therapeutically modulate host metabolism is
an emerging goal of microbiome research. In the intestine, bacterial urease converts host-derived
urea to ammonia and carbon dioxide, contributing to hyperammonemia-associated neurotoxicity
and encephalopathy in patients with liver disease. Here, we engineered murine gut microbiota to
reduce urease activity. Animals were depleted of their preexisting gut microbiota and then
inoculated with altered Schaedler flora (ASF), a defined consortium of 8 bacteria with minimal
urease gene content. This protocol resulted in establishment of a persistent new community that
promoted a long-term reduction in fecal urease activity and ammonia production. Moreover, in a
murine model of hepatic injury, ASF transplantation was associated with decreased morbidity and
mortality. These results provide proof of concept that inoculation of a prepared host with a defined
gut microbiota can lead to durable metabolic changes with therapeutic utility.
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Introduction
Dysbiosis, an abnormal and pathogenic state of the human microbiome, has been
implicated in inflammatory bowel diseases, atherosclerosis, obesity, diabetes, colon cancer, and
other diseases (1, 2). Fecal microbiota transplantation (FMT) is highly effective in the treatment of
refractory Clostridium difficile infection (CDI), providing proof of principle that a human disease
can be treated by engineering the gut microbiota (3), and further studies indicate that a healthy
microbiota can prevent disease acquisition (4).
Bacteria residing in the human gut produce urease, the activity of which is beneficial in
healthy hosts but pathogenic in hosts with liver disease. Urea produced by the liver as a waste
product is both excreted in urine and transported into the colon, where it is hydrolyzed by
bacterial urease into carbon dioxide and ammonia. Ammonia is then (a) utilized by the microbiota
for protein synthesis, (b) reabsorbed by the host, where it is incorporated into the nitrogen pool by
hepatic metabolism, or (c) excreted in the feces. Mammalian genomes do not encode urease
genes, so ammonia production results from bacterial urease activity acting on host-produced urea
(5, 6). Ammonia is also largely responsible for the alkaline pH of the colonic luminal environment,
acting to buffer the short-chain fatty acids also produced by the microbiota. Systemic ammonia
levels are elevated in patients with liver injury, chronic liver disease, or urea cycle defects, whose
hepatic abnormalities prevent the normal processing of ammonia delivered to the liver from the
intestinal tract. Circulating ammonia is correlated with damage to the CNS in patients with chronic
liver disease or inborn errors of metabolism, resulting in hepatic encephalopathy (HE) (7, 8).
Current treatments for HE and hyperammonemia are inadequate (8). Antibiotics (ABX)
traditionally used to treat HE, including aminoglycosides and metronidazole, are limited by side
effects and concerns for safety including ototoxicity, nephrotoxicity, and peripheral neuropathy (9,
10). Although rifaximin, a minimally absorbed ABX, has shown efficacy in the treatment and
prevention of HE (11, 12), potential development of antimicrobial resistance with long-term use
remains a concern. Lactulose is used to acidify feces and sequester ammonia as ammonium, but
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lactulose is poorly tolerated, resulting in poor adherence (13). In a mouse model of
thioacetamide-induced liver injury, a lactobacillus pro- biotic has been reported to reduce
ammonia levels and mortality (14), but these benefits have not been extended to human studies
(15, 16). While promising, studies of probiotic therapies in humans described to date have
suffered from methodological limitations, did not document long-term effects, and showed
consistently minimal effects on outcome, motivating efforts to engineer more resilient and
effective bacterial communities.
Here, we show that a synthetic microbial community lacking urease activity can be
installed in the gut to reduce the production of ammonia long term and thereby mitigate HE in a
mouse model. For proof-of-concept studies, we used altered Schaedler flora (ASF), which
consists of 8 murine gut commensal bacterial strains that were assembled in the 1970s and
standardized by the National Cancer Institute in 1978 (17). The strains were originally selected on
the basis of their persistence from generation to generation in germ-free mice and their ability to
restore a cecal morphology that is comparable to that of conventional mice. The ASF community
is innocuous, known to have a beneficial effect of inducing immune tolerance (18), and is used by
commercial mouse vendors to enhance the health of immunodeficient mouse strains. We found
that ASF is low in urease activity, making it useful for the studies of metabolic engineering
described here. Mixed results have been reported regarding the transfer of conventional
microbiota between rodents, with some studies reporting successful transfer with repetitive
inoculation (19), but others demonstrating that the use of ABX prevented transfer (20). We
developed methods for purging the gut microbiota from normally colonized mice that were then
transplanted with ASF by gavage. Transplantation of ASF was monitored longitudinally using
deep sequencing of DNA from fecal pellets, revealing highly efficient colonization in properly
prepared hosts. Over a 4-week monitoring period, ASF was partially displaced by selective
colonization with environmental Firmicutes, reaching a new steady state, but fecal ammonia
levels remained low. The engineered gut community was tested in thioacetamide (TAA) models
of acute and chronic liver injury (Figure 4.1A), in which we demonstrate that it reduced fecal
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ammonia levels, mortality, and neurobehavioral deficits. These results show that transplantation
of a defined minimal microbial community can alter metabolism in a predetermined fashion by
establishing a new gut microbiome, resulting in therapeutic benefits in disease models.

Results
Transplantation of ASF into previously colonized mice
The original ASF was composed of 8 bacterial strains. Over time, ASF has been
maintained in laboratory mice by fecal-oral transmission associated with cohousing in gnotobiotic
isolators. Thus, the composition of the ASF donor material used here was first characterized by
DNA isolation and shotgun metagenomic sequencing (16.9 Gb). Alignment to draft genome
sequences of ASF strains (21) documented the presence of 7 of the 8 original strains in our
samples (Figure 4.1B). Parabacteroides (ASF519) was the predominant lineage present in
pellets. Additional ASF strains consisted of roughly even proportions of Clostridia (ASF356,
ASF492, ASF500, ASF502) and Mucispirillum schaedleri (ASF457), accompanied by low levels
of Lactobacilli (ASF361). No high-quality read pairs mapped concordantly to strain ASF360. In
addition to ASF strains, 11% of reads mapped to the mouse genome, and a small fraction of
alignments mapped to probable artifacts including cloning vectors, metazoans, and additional
bacteria. We conclude that the bacteria in our donor material were mostly or entirely ASF strains.
To assess the persistence of ASF in mice housed under non-sterile conditions,
sequential fecal pellets were collected from 10 ASF-colonized mice that were transferred to
conventional SPF housing, DNA was purified from pellets, and the abundance and types of
bacteria present were assessed by quantitative PCR (qPCR) and deep sequencing of 16S rRNA
V1V2 gene segments (Sup. Figure 4.1). Copy numbers of 16S sequences per gram of stool
showed roughly similar abundance for ASF and conventionally colonized mice. Six of the eight
ASF strains were resolved at the depth of sequencing performed.
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ASF519 (Parabacteroides) accounted for approximately 75% of sequence reads at the
time of transfer of the mice. After approximately 2 months under nonsterile conditions, ASF519
remained the dominant taxon, and non-ASF taxa accounted for almost half of the sequence
reads. Evidently, ASF lineages persisted but did not entirely exclude other bacteria.
We reasoned that reduction of the endogenous microbiota would promote the transfer of
ASF, so we investigated the response of conventional microbiota to the oral delivery of 2 nonabsorbable ABX, neomycin and vancomycin. The 16S rRNA gene copy number was reduced by
approximately 4 logs within 72 hours of oral ABX initiation (P < 0.0001 for days 0, 1, and 2
compared with the mean of days 5–15), then returned to baseline 5 days after discontinuing ABX
(Figure 4.1C; P = 0.36 for comparison of ABX versus control at day 21), paralleling previous
studies (22, 23).
Fecal slurries obtained from ASF-colonized mice (Taconic) were then gavaged into
conventionally housed recipients for 7 days following a 72-hour pretreatment with oral ABX and a
12-hour intestinal purge using polyethylene glycol (PEG) (pretreatment with ABX and PEG is
henceforth termed “prepared”). PEG was used in our gut-cleansing protocol, because the use of
a purgative will likely be necessary to reduce bacterial load in the human intestinal tract due to
high biomass. For comparison, ASF transplants were carried out on conventional mice without
pretreatment and on germ-free mice. Mice that were treated with ABX and PEG and
subsequently transplanted showed normal numbers of bacteria by 16S qPCR copy numbers
within 10 days (data not shown).
Longitudinal fecal samples were analyzed by deep sequencing of 16S rRNA gene tags,
then the proportions of bacterial lineages detected were plotted as heatmaps, in which each row
shows a bacterial lineage and each column a fecal specimen (Figure 4.2). Conventional mice that
were not pretreated showed no increase in ASF lineages, despite ASF gavage (Figure 4.2,
Conventional + ASF gavage). A few preexisting lineages were present that were indistinguishable
from ASF using the V1V2 16S sequence window, but these did not increase in abundance after
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ASF gavage. A second group of mice (discussed above) were colonized with ASF from birth and
then moved to the non-sterile facility. These mice had high levels of ASF519 and detectable
levels of 4 other ASF strains (Figure 4.2, ASF-colonized).
These groups were then compared with (a) germ-free mice gavaged with ASF (referred
to herein as germ-free/ASF mice); and (b) conventional mice pretreated with ABX and PEG and
gavaged with ASF (referred to herein as prepared/ASF mice) (Figure 4.2, Germ-free + ASF
gavage and Prepared host + ASF gavage). Prior to ASF gavage, both the germ-free animals and
ABX-treated animals showed high levels of Lactococcus, a lineage found at high levels in mouse
chow (22), indicating that endogenous gut bacteria were mostly or entirely absent. Gavage of
these animals with ASF resulted in establishment of ASF lineages that persisted for the duration
of the sampling period. The communities were again dominated by ASF519.
Longitudinal evolution of the transplanted ASF community
Persistence of the transplanted ASF community was quantified using segmental
regression, plotting time against the proportion of ASF in each sample (Figure 4.3A).
Prepared/ASF mice and germ-free/ ASF mice transferred to non-sterile conditions were
compared and found to behave similarly. Initially, ASF comprised the majority of the community.
After transfer, the proportion of ASF slowly declined, constituting approximately 45% of the gut
community after 34 days (Davies’ test for a change in the slope P < 0.001; 95% CI for the
breakpoint was 27–41 days by segmented linear regression). After 34 days, the proportion of
ASF strains did not decrease for the duration of the experiment (120 days; P = 0.86).
Comparisons of community membership using unweighted UniFrac analysis of the 16S rRNA
gene-sequencing data showed that non-ASF lineages had colonized by day 14, and members
persisted for the duration of the study (Figure 4.3B), although the final abundance of non-ASF
lineages was not achieved until about day 30 (Figure 4.3A). Diversity of this new stable state
measured by the Shannon index approached that of the starting community (Figure 4.3C).
ASF519 (Parabacteroides) was the main taxon persisting in gavage from both germ-free/ASF and
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prepared/ASF hosts after 6 weeks, constituting approximately 40% and 50%, respectively, in
each group (Figure 4.2). As in humans, bacteria belonging to the Bacteroides genus were
dominant taxa in conventionally housed mice (24, 25).
The new lineages appearing after transplantation were specific (Figure 4.4). Members of
the Bacteroidetes phylum did not recolonize after ASF transplantation, suggesting that ASF519, a
member of the closely related Parabacteroides genus, may have occupied niches available to this
group. Several Firmicutes lineages did colonize over time, including lineages annotated as
Oscillibacter, Clostridium, and “other” Firmicutes (mostly of the order Clostridiales). Thus, the
community achieved a new steady state containing both ASF and environmentally acquired
lineages.
ASF has minimal urease gene content and activity
An analysis of the complete ASF genomes showed a minimal presence of urease genes.
No urease genes were identified in the predominant Parabacteroides ASF519. Two ASF
members contained urease genes, ASF492 and ASF361, but both were minor members of the
community after transplantation (Figure 4.2).
We then characterized urease activity, which we found readily detectable in pellets from
conventionally housed mice, but undetectable in pellets from mice colonized with ASF (Figure
4.5A). Similar results were obtained with pellets from mice treated with oral ABX that reduced the
bacterial load by 10,000-fold (Figure 4.5A). Intravenous delivery of 13C-urea to quantify urease
activity in vivo through the production of 13CO2 in a breath test revealed minimal hydrolysis in
ASF-colonized mice (Figure 4.5B).
Transplantation of ASF into prepared hosts led to a reduction in fecal urease activity
lasting for at least 80 days (Figure 4.5C). The novel community assembled after 30 days had low
urease activity, even though new lineages became established in addition to ASF (Figure 4.2).
Analysis of representative genomic sequences from these newly established genera showed that
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Oscillibacter, Dorea, Enterococcus, and Roseburia do not encode urease genes. We found that
Clostridium and the group annotated as “other” Firmicutes (mostly Clostridiales) were mixed, with
some representatives encoding urease genes, while others did not. It is unknown whether the
newly proliferating organisms lacked urease genes, or whether they encoded urease genes but
expressed them at low levels. Thus, the net effect of ASF colonization, together with the
establishment of additional lineages, was the achievement of a new steady state with low urease
activity. The new community persisted over the long term, as ASF-transplanted mice showed low
fecal ammonia levels for over 1 year in a specific pathogen–free (SPF) housing facility (data not
shown).
The resilience of this new community state following dietary stress was evaluated by
placing mice transplanted with ASF on a low-protein diet similar to that used for patients with
hyperammonemic inborn errors of metabolism (26). Fecal ammonia levels remained much lower
than those achieved by a low-protein diet alone, an effect that was durable for several months
(T.-C.D. Shen and G.D. Wu, unpublished observations). Another dietary stress, consumption of a
non-irradiated diet, led to the displacement of ASF by other bacteria within weeks after FMT, with
the predominant taxon Parabacteroides ASF519 being partially replaced by other taxa within the
Bacteroidetes phylum (Sup. Figure 4.2). Nevertheless, the reduction in fecal ammonia levels
compared with those at baseline remained significant for several months, even in mice on a nonirradiated diet (Figure 4.5D). Reductions in fecal ammonia levels have been correlated with
reductions in blood ammonia (14, 27, 28), indicating that changes in colonic ammonia production
and/or absorption can be associated with blood levels. The reduction in fecal ammonia may alter
levels of false neurotransmitter precursors produced by the gut microbiota and/or by the host,
since ammonia is a substrate for both, and this would lead to reduced formation of the biogenic
amines that are hypothesized to play a role in HE (29–31). Thus, we propose that fecal ammonia
is a useful biomarker for response of the host to the treatment of hyperammonemia.
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ASF transplantation reduces mortality and cognitive impairment in murine models of acute and
chronic liver injury
A major cause of morbidity and mortality associated with acute liver injury is the
development of HE. Since hyperammonemia is associated with the development of HE in
patients with impaired hepatic function (8), we asked whether the transplantation of ASF might
mitigate the effects of acute hepatic injury induced by TAA (32) treatment. Prepared/ASF mice
showed both a reduction in fecal ammonia levels (Sup. Figure 4.3A, Prepared + ASF) and
reduced mortality in response to high-dose TAA compared with mice with conventional microbiota
(Figure 4.6A). This finding was also seen in the setting of chronic liver injury in mice transplanted
3 weeks prior to the chronic delivery of TAA at low, escalating doses for 7 weeks (Figure 4.6B).
Compared with control mice, prepared/ASF mice demonstrated markedly reduced mortality rates
that were maintained over the 7-week period during which hepatic fibrosis developed in both
groups (refs. 33, 34; data not shown), consistent with a sustained reduction in fecal ammonia for
several months after ASF transplantation.
In mice, the TAA model has also been associated with neurobehavioral abnormalities
resembling HE in humans (35). Using a lower dose of TAA to reduce mortality, we analyzed
memory and spatial learning in a Y maze test (36) comparing prepared/ASF mice with mice
transplanted with normal microbiota (referred to herein as prepared/normal microbiota mice;
Figure 4.7 and Supplemental Figure 4.3B and 4.3C) as a control. The 80%–90% survival rates
were similar between the 2 groups at the lower TAA dose (Sup. Figure 4.3B). Fecal ammonia
levels were reduced in mice transplanted with ASF compared with those with normal microbiota
(Sup. Figure 4.3C). Prepared/normal microbiota mice showed a decrease in cognitive function
after TAA treatment, quantified as spontaneous alternations in a Y maze test, whereas
prepared/ASF mice treated with TAA were not different from untreated controls (Figure 4.7A).
Mice transplanted with either ASF or normal microbiota did not sufficiently differ in locomotor
activity after TAA treatment (as quantified by the total distance traveled and number of arm
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entries in the Y maze) to account for the difference in spontaneous alternations, although both
groups exhibited significantly less locomotor activity compared with untreated controls (Figure
4.7B and 4.7C). To exclude the possibility that ASF transplantation directly reduced liver injury,
we measured plasma alanine aminotransferase (ALT) and quantified histologic evidence of
hepatocyte necrosis (Sup. Figure 4.4, A and B). Both revealed that liver damage induced by TAA
was not reduced by either ASF transplantation or ABX treatment. Thus, improved survival and
behavioral performance were associated with reduced ammonia levels and not improved
locomotor activity or liver injury.

Discussion
The success of FMT in the treatment of CDI establishes that transplanting a resilient
microbial community can alter a dysbiotic microbiota and thereby treat disease. Feces, however,
contains not only bacteria but also a multitude of archaea, fungi, and viruses, so there is concern
for safety (37), motivating the development of defined microbial consortia for human inoculation
that have well-characterized biological properties and respond to the gut environment in
predictable ways. Here, we show that a defined minimal consortium of bacteria, ASF (17, 18), can
durably reprogram the composition and metabolic function of the gut microbiota when inoculated
into a properly prepared host. By taking advantage of the minimal urease activity in ASF, we
provide evidence that reprogramming the gut microbiota can lead to lower fecal ammonia levels
and mitigate the morbidity and mortality associated with liver damage.
The endogenous gut microbiota needed to be depleted by treatment with oral ABX and
PEG for efficient transfer of the ASF community into conventionally housed mice. After the gut
purge, transfer was as effective as that into germ-free recipients. Tracking by sequencing
suggested an orderly succession of lineages. After ASF transplantation, the predominant ASF519
strain appeared at the earliest times after gavage. Mucispirillum schaedleri (ASF457) and
Ruminococcaceae (ASF500) also appeared early on. The last to appear was the Clostridium
species (ASF356) on day 14 in some mice, 1 week after gavaging was complete, perhaps
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indicating the need for development of a specific niche that permitted the establishment of more
fastidious taxa. Most mice contained a Lactobacillus strain indistinguishable from ASF361 prior to
transplantation, so this lineage could not be tracked with the methods used. The observed
succession may be similar to the succession of bacterial taxa in human infants, as consumption
of oxygen by initial gut colonizers allows the expansion of bacterial clades that are obligate
anaerobes (38, 39).
By monitoring the composition of the transplanted ASF community over a 4-month period
using 16S rRNA gene sequencing, we were able to assess the persistence of the community in
the nonsterile SPF environment. The ASF community did not fully exclude other taxa. The
community appeared to achieve a new steady state, whereby both types of transplanted hosts
came to resemble the mice colonized with ASF from birth and housed long term in an SPF
environment. In each of these 3 groups, Parabacteroides (ASF519) remained the dominant
taxon. Bacteria of the Bacteroides genus commonly dominate the human and murine gut
microbiota (24, 40–43), but new Bacteroides did not accumulate over time in ASF-colonized mice,
suggesting that Parabacteroides may have excluded Bacteroides, reminiscent of the trade-off
between Bacteroides and Prevotella in human gut (24, 44–46). The mechanism by which
Parabacteroides excludes Bacteroides is unknown but, due to their taxonomic and functional
similarities, may involve competition for limiting resources (47) such as has been shown for
glycans and the competition between Bacteroides species in the colonic crypt (48). Over time, the
Parabacteroides and environmental Firmicutes established a new steady state approximating the
composition of conventional microbiota in humans and mice (40, 41, 49), possibly involving a
syntrophic relationship between these lineages (50).
There was a sustained reduction in fecal urease enzymatic activity and ammonia
production upon transfer of ASF into prepared mice. There was no return of urease activity
several months after transfer, despite a substantial increase of non-ASF taxa. A possible lack of
urease genes in many of the Clostridium taxa that accumulated after transplantation may explain
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the persistently reduced urease activity, although we cannot exclude other mechanisms, since
the regulation of urease enzymatic activity is known to be complex (6).
Production of ammonia by the gut microbiota has been implicated in host nitrogen
balance (51–53), so there is a theoretical risk that a urease-free community might have an
adverse effect on protein balance and growth of the host. However, we have tracked mice for
over 1 year after ASF transplantation and observed no adverse effects on their body weight or
mortality. ASF is acknowledged to be an innocuous bacterial consortium in mice with beneficial
effects on immune tolerance (18). Nevertheless, additional safety studies will need to be
performed using a humanized version of ASF in rodent models before human studies can be
contemplated.
In summary, given that HE is a major contributor to morbidity and mortality in liver
disease (54), transplantation of next-generation engineered communities based on ASF, coupled
with improved preparation of the host as described here, represents a promising approach to
more effective therapy.

Methods
Animals
Feces from CB17 SCID mice colonized with ASF (Taconic) were the source of ASF in the
transplantation experiments. Mice in this study were maintained in a standard SPF barrier facility
and were fed irradiated AIN-76 chow (Research Diets Inc.) containing protein as 21% of the
kilocalories. For the nonirradiated diet experiment, we used Laboratory Rodent Diet 5001
(LabDiet) containing protein as 29% of the kilocalories. For microbiota transfer experiments, 0.1 g
feces was diluted 10-fold in PBS. For Figures 4.2 to 4.4, germ-free recipient mice were purchased
from Taconic, as were the conventionally housed Swiss Webster mice used in the first
experiment. For all other experiments, we used either male or female 8-week-old C57BL6 mice
(The Jackson Laboratory). Pretreated conventional mice were prepared for inoculation by oral
74

delivery of ABX in the drinking water (1.125 g aspartame, 0.15 g vancomycin, and 0.3 g neomycin
in 300 ml sterile water) for 72 hours. During the final 12 hours, the water supply was exchanged
with a 10% PEG solution (Merck), and the mice were fasted. The mice were then inoculated daily
with feces by oral gavage for 5 to 7 days. Fecal pellets were collected for bacterial taxonomic and
biochemical analyses at the time points indicated in the figures (Figure 4.1C, Figures 4.2- 4.4,
Figure 4.5A, C, and D, Sup. Figure 4.1, Sup. Figure 4.2, and Sup. Figure 4.3A and C).
DNA isolation, qPCR, sequencing, and analysis
DNA was isolated from stool as previously described (46, 55). Bacterial 16S rRNA gene
sequences were PCR amplified with primers binding to the V1V2 region (46, 55) using bar-coded
primers (56, 57). Shotgun metagenomic data were collected using the TruSeq library preparation
method and a HiSeq instrument (both from Illumina). Sequence reads were quality controlled and
analyzed using the QIIME pipeline with default parameters (58). Sequence data sets were
deposited in the NCBI’s Sequence Read Archive (SRA) database (accession number
SRP058968).
Urease activity and ammonia assays
Fecal ammonia levels were determined using an Ammonia Assay Kit (ab83360; Abcam).
Fecal pellets were suspended in the assay buffer provided at a concentration of 1 mg/10 µl and
centrifuged at 13,000 g for 10 minutes at room temperature to remove insoluble material.
Ammonia concentration was then determined according to the kit protocol.
Fecal urease activity was measured by suspending fecal pellets in 0.5 mM HEPES
buffer. After sonication and centrifugation, the supernatant was incubated for 30 minutes at 37°C
with 1 µCi 14C-labeled urea (19.9 mCi/mmol; catalog ARC-0150; American Radiolabeled
Chemicals) in a sealed container. The air was purged into a trap containing 2.5 ml of 0.2 M
benzethonium hydroxide in methanol (catalog 82156; Sigma-Aldrich), and 14CO2 activity was
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quantified by liquid scintillation counting. A standard curve was generated using purified E. coli
urease (150 IU/mg; catalog 22060744-1; BioWORLD).
The urease breath test was performed on 4-hour fasted mice by placing them in a sealed
glass chamber. A total of 4 cc air was withdrawn from the chamber using a gas-tight syringe after
10 minutes and injected into 12 ml (gas-helium) Exetainer glass vials (438B; Labco) to establish a
baseline CO2 level. The mouse was then injected via the tail vein with [13C]urea (150 µg/g body
weight) (CLM-311-0; Cambridge Isotope Labs). Blood was collected 15 minutes after injection to
assess total urea and isotopic enrichment in [13C]urea. Enrichment in expired air was measured
at 30, 60, 120, 180, and 240 minutes after injection of the labeled urea. The 13CO2/12CO2 ratio
was measured in gas samples with a Finnigan DELTAplus isotope ratio mass spectrometer
(Thermo Fisher Scientific). A commercial CO2 source (Airgas) was used as the standard. The
measurement of isotopic abundance in [13C]urea in plasma involves the elimination of CO2 from
the sample and the subsequent conversion of urea to CO2 with commercially available urease
(59).
Induction of acute liver injury and hepatic fibrosis
Mice in the high-dose TAA acute liver injury model were given a single i.p. injection of
TAA at 600 mg/kg. In the low-dose TAA acute liver injury model, mice were given a single dose of
TAA at 300 mg/kg by i.p. injection, with subsequent performance of the Y maze neurobehavior
test 48 hours after TAA injection (see Neurobehavior test below). In the chronic liver fibrosis
model, all mice were given TAA by i.p. injection 3 times weekly, with the initial 100 mg/kg dose
being decreased to 50 mg/ kg during the first week, given the rate of morality, followed by dose
escalation to 100 mg/kg during the second week, 200 mg/kg during the third week, 300 mg/kg
during the fourth week, and 400 mg/kg during the fifth to seventh weeks of TAA administration.
Neurobehavior test
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The Y maze test was conducted to assess the rodents’ memory and spatial learning (60).
The maze consists of 3 identical and equally spaced arms, and the natural tendency of the
mouse is to investigate a new arm of the maze rather than return to the one previously visited. A
mouse with a cognitive deficit would exhibit less spontaneous alternation, defined as entering all
3 arms in 3 sequential arm entries. Control mice typically exhibit greater than 60% spontaneous
alternation. In this experiment, mice were allowed to habituate to the testing room, where there
were no overt visual cues, for 30 minutes prior to testing. The maze was cleaned with 70%
ethanol before use and between trials to eliminate odor cues. A trial started when a mouse was
released into 1 arm of the maze (same arm for each mouse). As the mouse navigated the maze,
each arm entry was noted. At the end of the timed trial (8 minutes), total arm entries were
summed and spontaneous alternations determined by the following formula: percentage of
spontaneous alternations = [(number of alternations)/(total arm entries − 2)] × 100. Trials were
video recorded as well as graded during the procedure. Image analysis software was used to
measure the total distance traveled by each mouse during the trials.
Statistics
Results are expressed as the mean ± SEM. Statistical significance among 3 or more
groups was assessed by ANOVA. A 2-tailed Student’s t test and paired-sample t test were used
for direct comparisons between 2 groups and within groups, respectively. Tukey’s test was used
to adjust for multiple comparisons. Kaplan-Meier survival curves were compared using the logrank test. A P value of less than 0.05 was considered statistically significant.
Study approval
All animal studies were performed with the approval of the IACUC of the University of
Pennsylvania.
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Figures
Figure 4.1. Transfer of ASF into a previously colonized murine host. (A) Diagram of the
experimental method. Ure, urease. (B) Shotgun metagenomic analysis of stool from ASFcolonized animals used for gavage in this study. Proportions of the different ASF lineages and
other organisms are indicated by the color key. (C) Time course of 16S rRNA gene copy numbers
during oral ABX treatment (14 days, vancomycin and neomycin) and upon discontinuation
ofABXonday15(n=3pergroup). *P < 0.0001, for days 0–2 compared with the average of days 5–
15 in the ABX group; **P < 0.05, between the ABX and control groups. Paired-sample t test and
2-tailed Student’s t test.
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Figure 4.2. Heatmap showing the relative abundance of bacterial lineages over time in
ASF-colonized mice and controls. Rows indicate bacterial lineages as annotated on the left.
Relative abundance is indicated by the color key at the bottom of the figure. Columns summarize
the sequencing results from individual fecal specimens. Elapsed time in days is shown along the
bottom. The groups studied are indicated at the top of the heatmap and include (from the left)
conventional mice that were gavaged with ASF stool without preparation (Conventional + ASF
gavage); mice that were ASF colonized from birth, then transferred to a nonsterile SPF facility
(ASF-colonized); mice that were germ-free, then gavaged with ASF (Germ-free + ASF gavage);
and conven- tional mice that were prepared with ABX and PEG treatment, then gavaged with
ASF (Prepared host + ASF gavage).
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Figure 4.3. Development of a stable gut microbial community nucleated by inoculation
with ASF. (A) Segmented regression analysis of communities in mice that were either germ-free
or prepared conventional mice subjected to ASF gavage. The y axis shows the proportion of ASF
lineages inferred from 16S rRNA gene tag pyrosequencing data. The x axis shows the number of
days after transfer. Segmented regression analysis showed 2 phases, indicating a slow decline in
the ASF proportion up to about day 30, followed by establish- ment of a new steady state
consisting of approximately 40% ASF lineages. (B) Principal coordinates analysis (PCoA)
ordination over time. Changes in community membership over time were analyzed using
unweighted Unifrac (61). Progression of time is indicated by a gray arrow. (C) Shannon diversity
of gut microbiota over time in the 4 hosts described in Figure 2. n = 5 per group for Conventional
+ ASF gavage, Germ-free + ASF gavage, and Prepared + ASF gavage. n = 10 for ASFcolonized.
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Figure 4.4. Comparison of non-ASF sequence reads from either Bacteroidetes or
Firmicutes, illustrating selective repopulation with environmental Firmicutes. (A and B)
Groups are color coded and represent change over time. n = 5 per group for Conventional + ASF
gavage, Germ-free + ASF gavage, and Prepared + ASF gavage. n = 10 for ASF-colonized.
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Figure 4.5. Transfer of ASF leads to a reduction in urease activity and fecal ammonia
levels. (A) Urease activity in the feces of a conventionally housed mouse versus
a mouse treated with ABX and a mouse colonized with ASF. (B) In vivo urease activity in
conventionally housed (n = 5) and ASF-colonized mice (n = 5) quantified by the release of 13CO2
after i.v. injection of 13C-urea. (C) Fecal urease activity at the indicated time points after
transplantation of ASF into prepared mice fed an irradiated diet (n = 3). (D) Fecal ammonia levels
before and after transplantation of ASF into prepared mice fed a nonirradiated diet (n = 5). *P <
0.01; **P < 0.001. Tukey’s test for multiple comparisons.
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Figure 4.6. ASF transplantation into prepared mice reduces mortality after thioacetamideinduced hepatic injury and fibrosis. (A) Kaplan- Meier survival curves of high-dose TAAinduced acute hepatic injury in conventional versus prepared/ASF mice (n = 15 per group). (B)
Kaplan- Meier survival curves of chronic, thrice weekly TAA administration at low, escalating
doses, initiated 3 weeks after ASF transplantation (n = 15 per group). Survival curves were
analyzed by the Kaplan-Meier method using the log-rank test.
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Figure 4.7. ASF transplantation into prepared mice restores cognitive, but not locomotor,
deficits after thioacetamide-induced hepatic injury. (A) Spontaneous alternations after TAA
treatment quantified by Y maze testing in prepared mice that were transplanted with either normal
microbiota (n = 10) or ASF (n = 11) compared with untreated control mice (n = 5). *P < 0.05, by
2-tailed unpaired Student’s t test; P = 0.04, by ANOVA. (B) Total distance traveled and (C)
number of arm entries in the Y maze in prepared/ASF and prepared + normal microbiota mice
after TAA treatment compared with untreated control mice. ***P < 0.001, by 2-tailed unpaired
Student’s t test; P < 0.001, by ANOVA.
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Wu G. 2016. Dietary Regulation of the Gut Microbiota Engineered by a Minimal Defined
Bacterial Consortium.

Abstract
We have recently reported that Altered Schaedler Flora (ASF) can be used to durably engineer
the gut microbiota to reduce ammonia production as an effective modality to reduce morbidity and
mortality in the setting of liver injury. Here we investigated the effects of a low protein diet on ASF
colonization and its ability to engineer the microbiota. Initially, ASF inoculation was similar
between mice fed a normal protein diet or low protein diet, but the outgrowth of gut microbiota
differed over the ensuing month. Notable was the inability of the dominant Parabacteroides ASF
taxon to exclude other taxa belonging to the Bacteroidetes phylum in the setting of a low protein
diet. Instead, a poorly classified yet highly represented Bacteroidetes family, S24-7, returned
within 4 weeks of inoculation in mice fed a low protein diet, demonstrating a reduction in ASF
resilience in response to dietary stress. Nevertheless, fecal ammonia levels remained significantly
lower than those observed in mice on the same low protein diet that received a transplant of
normal feces. No deleterious effects were observed in host physiology due to ASF inoculation
into mice on a low protein diet. In total, these results demonstrate that low protein diet can have a
pronounced effect on engineering the gut microbiota but modulation of ammonia is preserved.

Introduction
The gut microbiota responds to multiple environmental stressors such as diet [1-3],
antibiotic use [4], inflammation of the intestinal tract [5], and infection of the host with enteric
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pathogens [6]. By studying the gut microbiota in pediatric patients with Crohn’s disease, we have
recently shown that the effects of these factors may be independent even if present
simultaneously [7]. Amongst these, the impact of diet has received considerable attention as a
potential modifiable factor that shapes the composition and/or function of the gut microbiota to
prevent and/or treat disease [8]. The high-level efficacy of fecal microbiota transplantation (FMT)
in the treatment of Clostridium difficile infections (CDI) is proof of concept that inoculating a host
with a consortium of microbes has a meaningful effect on the composition of the gut microbiota
[9]. The use of feces could be considered an untargeted approach with potential risks [10], but
growing evidence suggests that the use of defined microbial consortia could be developed to treat
disease [11, 12]. We have recently shown that the gut microbiota can be durably reconfigured to
reduce fecal urease activity and ammonia production through oral inoculation of Altered
Schaedler Flora (ASF), a defined microbial consortium that contains minimal urease gene content
[12]. ASF comprises 8 murine gut commensal bacterial strains assembled in the 1970s and
standardized by the National Cancer Institute in 1978 [13]. It is now commonly used to create
gnotobiotic mice and/or to enhance the health of immunodeficient mouse strains.
Examples of co-metabolism between the gut microbiota and its mammalian host requiring
host-derived substances include bile acids, mucous, and urea. The latter is particularly important
for nitrogen flux between the host and the gut microbiota [14, 15]. As the primary source of
nitrogen, dietary protein is essential to the synthesis of nucleic acids, amino acids, and other
nitrogenous compounds. The catabolism of dietary protein by the host leads to hepatic formation
of urea, a nitrogenous waste product that is excreted through the urine or delivered into the colon,
where hydrolysis by bacterial urease results in the production of carbon dioxide and ammonia.
Ammonia is a shared substrate for the synthesis of proteins, amino acids, and other small
molecules by both the host and its microbiota. Although generally thought to be nutritionally
beneficial to the host by enhancing nitrogen recycling, the production of ammonia by the gut
microbiota can have deleterious effects in the setting of altered hepatic function, resulting in the
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development of neurotoxicity [16-18]. Under such conditions, a low protein diet (LPD) can be
used to reduce systemic ammonia levels [19, 20].
By inoculating mice with ASF after the endogenous microbiota has been reduced through
the use of antibiotics and polyethylene glycol (PEG), the composition of the gut microbiota can be
durably modified in composition as well as function. Functionally, there was a long-lasting
reduction in fecal ammonia that was effective in reducing morbidity and mortality in the
thioacetamide model of liver injury [12]. Since (1) the absorption of fecal ammonia produced by
the gut microbiota may be an important source of nitrogen for the host especially in the setting of
dietary protein restriction [14], and (2) low protein diets are used clinically in patients with
hyperammonemic inborn errors of metabolism [21], there are a number of questions about the
impact of diet on the engineering of the gut microbiota to reduce ammonia production. What is the
effect of a LPD on the ability of a defined bacterial consortium to engraft into the gut? Does a LPD
have an effect on the composition of the engineered microbiota? Will the ammonia reduction by
microbiota engineering be sustained and exhibit lower levels than those achievable by a LPD
alone? And lastly, will a significant reduction in gut microbiota ammonia production be deleterious
to the host on a LPD?
Here, we address these questions by inoculating mice on a LPD with either feces from
conventionally-reared mice (Normal Feces, or NF) or with ASF, monitoring the resultant
composition of the gut microbiota over time by 16S tagged sequencing, assessing functionality by
quantifying fecal ammonia levels, and investigating the impact on the host by metabolic profiling.
Although a LPD has no effect on the ability of ASF to engraft into the gut of the host upon
inoculation, the resultant engineered state of the microbiota is altered primarily due to the reemergence of S24-7, a specific bacterial taxonomic family within the Bacteroidetes phylum.
Despite this alteration, fecal ammonia levels remain diminished and without consequence to the
metabolic physiology of the host on a LPD.
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Results
LPD impacts host physiology and nitrogen metabolism but modestly alters the composition of the
gut microbiota
We first set out to investigate the effects of a LPD on both the murine host and the gut
microbiota. Fifteen adult female C57BL6J mice were placed on an open source irradiated purified
rodent diet containing normal amount of dietary protein at 21% by kilocalories (AIN-76A),
henceforth referred to as normal protein diet (NPD, Sup. Table 5.1) for one week upon arrival into
the University of Pennsylvania SPF vivarium. Subsequently, ten of the 15 mice were switched to
an irradiated low protein diet (LPD, Sup. Table 5.1) formulated using AIN-76A as the base that
contains 3% protein by kilocalories. The LPD was made isocaloric by proportionally increasing
carbohydrate content while keeping fat content unchanged. The remaining 5 mice continued to be
fed the NPD. We monitored physiological changes in these mice using body weight and food
intake measurements as well as body composition determination via nuclear magnetic resonance
(NMR) imaging. We found that compared to NPD-fed mice, LPD-fed mice exhibited poor weight
gain despite equivalent caloric consumption (Figure 5.1A). LPD-fed mice also demonstrated
increased fat mass and decreased lean mass (Figure 5.1B and 5.1C). Corresponding to a
reduction in serum urea level compared to NPD-fed mice (Figure 5.1D), LPD-fed mice exhibited
significant reductions in fecal urea and fecal ammonia levels after ten weeks on the LPD (Figure
5.1E and 5.1F). These results are consistent with the fundamental role that dietary protein plays
in host nitrogen balance. Reduction in dietary protein may have an effect on the gut microbiota by
reducing the delivery of urea to the colonic environment leading to the reduction in fecal ammonia
levels.
16S tagged sequencing (1045 to 5305 reads per sample, median = 3448 reads) revealed
modest yet distinct differences in the composition of the fecal microbiota in mice after placement
on the LPD. These difference can be visualized in principal coordinates analysis of weighted
(Figure 5.2A) and unweighted (Figure 5.2B) UniFrac distance. The LPD led to a significant
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increase in the diversity of the gut microbial community as assessed by the Shannon diversity
index (Figure 5.2C and Sup. Figure 5.1). The LPD also led to significant increases in the relative
abundance of Mollicutes and Coriobacteria and a decrease in the Firmicutes classes
Erysipelotrichi and Clostridia (Figure 5.2D and 5.2E).
LPD has no effect on the initial engraftment of ASF into the host microbiota
We have previously shown that there is a reduction in gut bacterial biomass upon
treatment of mice with oral antibiotics (vancomycin and neomycin) and PEG, thus permitting the
engraftment of ASF upon inoculation by oral gavage [12]. However, the effect of a LPD on the
engraftment of ASF into the gut of a prepared host remains unknown. After preparation with
antibiotics and PEG, we orally inoculated five of the LPD-fed mice with ASF (herein referred to as
“ASF-transplanted”). As a control group, we transplanted the other five LPD-fed mice using feces
from conventionally-reared donor mice (herein referred to “NF-transplanted,” for Normal Feces).
Using 16S rRNA tagged sequencing, we tracked taxonomic alterations in the gut microbiota over
time. We found that NF-transplanted mice exhibited minimal change in the composition of their
gut microbiota (Sup. Figure 5.2). However, the gut microbiota of ASF-transplanted mice
underwent a shift in composition in a similar fashion to that previously observed in NPD-fed mice
transplanted with ASF [12], as shown in Figure 5.3A and 5.3B. In particular, the shifts along PC1
in both cohorts of mice represent changes due to the initial ASF inoculum (compare days 0 to 14
in both groups), whereas differences between the two cohorts of mice along PC2 may represent
the effect of diet. These findings suggest that a LPD does not affect the initial engraftment of ASF
into the host microbiota.
Diet affects the resilience of the gut microbiota engineered by inoculation with ASF
By tracking the composition of mice inoculated with ASF, we determined the effect of a
LPD on the ability of ASF to engineer a different microbiota composition. In the setting of a NPD,
we previously observed that ASF transplantation led to the development of a new steady state
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community after one month composed of both ASF and the return of selected taxa of the
Firmicutes phylum, but no non-ASF Bacteroidetes [12]. We proposed that Parabacteroides
ASF519, the dominant taxon in ASF in feces, may have prevented the return of other
Bacteroidetes taxa by competitive niche exclusion. Tracking compositional changes in the gut
microbiota over time, we found that in the setting of the LPD, the gut microbiota engineered by
ASF inoculation developed into an alternative rich community with diversity similar to that on the
NPD (Figure 5.3C). However, ASF519 did not suppress the return of other Bacteroidetes.
Instead, Bacteroidetes S24-7, a poorly classified yet common bacterial taxon in the commensal
murine gut microbiota [22, 23], returned after ASF transplantation and reached an equilibrium
state with ASF519 (Figure 5.4 and Sup. Figure 5.3). We plotted the progression of the
transplanted ASF community over time. We found that ASF reached a new steady state in the
setting of the LPD at around 4 weeks after transplantation, similar to what we previously observed
in the setting of the NPD [12] (Figure 5.3A and 5.3B). However, this steady state more closely
resembled the endogenous microbiota, likely as a result of the return of S24-7 on the LPD (best
observed in Figure 5.3A along PC1 – compare the solid to dotted grey line). Overall, these
findings suggest that ability of ASF lineages to compete is reduced in the presence of a LPD.
The ASF-engineered gut microbiota lowers fecal ammonia more effectively than LPD alone
We have previously shown that ASF transplantation durably reduces fecal ammonia by
decreasing fecal urease activity [12]. Since a LPD itself mainly reduces fecal ammonia levels by
decreasing the delivery of urea to the colon (Figure 5.1E and 5.1F), we sought to determine
whether the ASF-engineered microbiota would be able to reduce fecal ammonia levels below
those achieved by a LPD alone. We measured fecal urea and fecal ammonia levels in mice at
baseline on the NPD, after ten weeks on the LPD, and compared ASF and NF transplantation on
the LPD. As shown in Figure 5.5A, after the initial reduction in fecal ammonia levels induced by
the LPD, ASF transplantation reduced fecal ammonia further than did NF transplantation. The
ability of the ASF-engineered microbiota to lower fecal ammonia levels below those achieved by
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the LPD alone is likely due to the reduction in fecal urease activity since there was no difference
in fecal urea levels after NF and ASF transplantation (Figure 5.5B). These results indicate that the
functionality of the ASF-engineered gut microbiota is not significantly altered in the setting of a
LPD despite alterations in its composition.
The low fecal urease and fecal ammonia-producing microbiota engineered by ASF inoculation
does not exacerbate host metabolic dysfunction induced by LPD
Urea is a nitrogenous waste product, but it is thought to contribute to host nutrition via
urea nitrogen recycling by intestinal bacterial urease in both ruminants and non-ruminants,
leading to microbial and/or host synthesis of peptides, amino acids, and other small molecules
[14]. We asked whether this role of urea may become important for host physiology in the setting
of a LPD, where systemic nitrogen is reduced. After transplanting the above cohort of mice with
ASF or NF, we continued to monitor their body weight, food intake, and survival. Remarkably,
despite the absence of colonic urea nitrogen recycling, ASF-transplanted mice did not differ
significantly from NF-transplanted mice (Figure 5.5C, 5.5D, and Sup. Figure 5.4). Thus, in the
setting of a LPD, ASF transplantation does not lead to significant detrimental changes to host
physiology and metabolism.

Discussion
The success of FMT in the treatment of recurrent Clostridium difficile infections provides
proof of concept that the gut microbiota can be a target for the treatment of disease in humans.
The use of fecal transfer will likely be replaced by the use of defined microbial consortia with
specific biological properties. As proof of concept, we have shown in murine models that a
defined consortium of eight bacteria, known as Altered Schaedler Flora (ASF), can be used to
engineer the gut microbiota with altered functionality, namely a reduction in fecal urease activity
and ammonia production [12]. Critical to the success of this strategy is the substantial reduction in
the biomass of the baseline microbiota to provide a niche into which the bacterial inoculum can
engraft.
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An important consideration for engineering the gut microbiota is resilience to
environmental stress. An optimally engineered microbiota would be a rich community that stays
intact in the presence of environmental stress. Diet is an important environmental stressor on the
gut microbiota that should be considered when engineering gut microbial communities. As one
example, the low ammonia-producing microbiota engineered by ASF, which has functional
durability for several months in mice fed an irradiated diet, shows reduced resilience when the
mice are fed a non-irradiated diet [12]. We chose to study the impact of dietary protein on the
resilience of the ASF-engineered microbiota for several reasons: 1) Dietary protein has been
shown to influence the composition of the gut microbiota in gnotobiotic mice [24]; 2) Protein
consumption regulates the production of hepatic urea that may affect colonic urea delivery to the
gut microbiota [14, 25]; 3) Protein-restricted diets are an important therapeutic modality for
patients with hyperammonemic inborn errors of metabolism [20, 26].
Unlike the modulation of fat and fiber in mice, which have been shown to have a strong
effect on the composition of the murine gut microbiota [1, 24], we show that severe restriction of
dietary protein had a modest effect. Within the Firmicutes phylum the Clostridia and
Erysipelotrichi classes decreased significantly on a LPD, consistent with the preference of taxa
within Firmicutes, particularly Clostridia species, to metabolize amino acids and peptides [27, 28].
Alternatively, since we show that a LPD reduces serum urea levels with reduced delivery to the
colon resulting in lower fecal ammonia levels, an alteration in nitrogen flux via ammonia into the
gut microbiota [29, 30] may also have an effect on the composition of the bacterial microbiota.
Since we balanced protein with carbohydrate in the composition of the purified rodent
diet, it is difficult to ascertain if the differences in the composition of the gut microbiota are due
primarily to alterations in protein or in carbohydrate. We found that two bacterial phyla present at
low abundances increased significantly on a LPD. Specifically, the classes Mollicutes
(Tenericutes phylum) and Coriobacteria (Actinobacteria phylum) increased on a LPD. Previous
work has shown that Mollicutes proliferated on a typical Western diet characterized by high96

fat/high-sugar content, likely because of their ability to import and process simple sugars [31].
Thus, an increase in the abundance of Mollicutes that we observed on a LPD could be due to the
increase in carbohydrate content rather than the reduction in protein content. Another study also
showed that gut colonization by Actinobacteria and Tenericutes was strongly correlated with
decreased hepatic levels of glycogen and glucose [32], further suggesting the interplay between
the host and these two phyla may be closely related to carbohydrate metabolism.
Despite the effect of a LPD on the composition of the gut microbiota at baseline, this did
not have an effect on the initial engraftment of ASF at 2 weeks, demonstrating that the use of
antibiotics and PEG effectively prepared the environment of the gut for inoculation by a minimal
defined bacterial consortium. Subsequently, development of the resultant engineered microbiota,
determined by emergence of various bacterial taxa in addition to ASF, was distinctly different in
mice fed a NPD versus a LPD. On a NPD, we previously showed that the dominant taxon
Parabacteroides (ASF519) was able to exclude the entire Bacteroidetes phylum yet permit the
reappearance of specific taxa belonging to the Firmicutes phylum. The observation that bacterial
lineages with similar phylogeny exhibit competitive niche exclusion has been demonstrated in the
Bacteroides genus where successful competition for carbohydrate substrates plays an important
role [33]. By contrast, on a LPD, the resultant engineered microbiota appears to be more similar
to baseline primarily due to the reemergence of a single bacterial taxon belonging to the
Bacteroides family, S24-7.
S24-7 has been previously recognized as a dominant taxonomic group in the murine
microbiota. It was first characterized by Salzman et al., who referred to the taxon as “mouse
intestinal bacteria” [22]. The S24-7 taxon is phylogenetically distinct from other named genera in
the order Bacteroidales. The taxon has been reported as altered in several recent mouse studies:
it was increased in proportion following partial hepatectomy [34], associated with co-infection by
Hymenolepis spp. [35], and decreased in proportion following antibiotic treatment for parenteral
nutrition-associated liver injury [36]. However, to our knowledge, no study has previously
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characterized competition between S24-7 and other Bacteroidetes species in mice. The S24-7
taxon is typically encountered at very low (<1%) abundance in fecal samples from human
populations. However, one study of a previously uncontacted Amerindian population reported the
taxon to be enriched in isolated Yanomami Amerindians relative to Guahibo Amerindian,
Malawian, and U.S. subjects [37]. The average abundance of the taxon in Yanomami
Amerindians was reported to be nearly 5% of total bacteria, suggesting a potential role for S24-7
in the human gut.
Upon reduction of bacterial biomass through a combination of antibiotics and
polyethylene glycol (PEG), S24-7 is no longer detectable and shows no return over time after
mice have been inoculated with ASF. Since both Paracteroides (ASF519) and S24-7 are closely
related within the Bacteroidetes phylum, we speculate that S24-7 may be co-excluded from the
luminal gut environment by ASF519 through competitive niche exclusion, a mechanism that has
been hypothesized as the basis for the inversely-related proportions of Bacteroides and
Prevotella in the human gut microbiota [2, 38], a predominant feature of “enterotypes” [39]. From
a mechanistic standpoint, the basis of competitive niche exclusion may involve the competition of
metabolic substrates as has been demonstrated for Bacteroides species in a reductionist model
system [33]. Since S24-7 reappears and co-exists at approximately equal levels with ASF519 in
LPD-fed mice, the alteration of substrate availability via diet may have altered the luminal
environment of the gut that reduces the need for competition between these two taxa. For
example, a LPD may have altered the balance of nitrogen flux into the gut microbiota via the
uptake of ammonia. Indeed, despite the return of S24-7 and the similarities between the
composition of a gut microbiota of a conventionally-housed mouse and the ASF-engineered
community established in LPD-fed mice, fecal ammonia levels remained much lower in ASFtransplanted mice that those transplanted with normal feces. This suggests that S24-7 may be
urease negative. Further elucidation of such mechanism(s) will require genomic characterization
of S24-7 along with an evaluation of its biological properties.
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The quantification of fecal ammonia was used to determine the impact of microbiota
composition on the function of the community. Despite the modest alterations in the gut
microbiota induced by the consumption of a LPD, there was a significant reduction in fecal
ammonia levels reflecting the reduced abundance of urea substrate available for hydrolysis by
the gut microbiota. This observation emphasizes the notion that diet may have an indirect impact
on the gut microbiota by alteration of the host similar to the outgrowth of a pathobiont due to the
enhanced production of sulfated bile acids in mice fed milk fat [40]. Importantly, engineering of
the gut microbiota using ASF led to a reduction in fecal ammonia levels significantly greater than
that observed on a LPD.
Since ammonia, produced by the gut microbiota via urease activity, is absorbed by the
host where it can be used for amino acid synthesis, it has been hypothesized that this form of
nitrogen recycling may be important for host health especially under conditions of limited protein
intake [14, 41]. This might be a significant limitation of a strategy focused on reducing gut
microbiota ammonia production for the treatment of hyperammonemia and hepatic
encephalopathy [12]. Although LPD-fed mice did not exhibit growth, as would be expected, ASF
transplantation with subsequent robust reduction of fecal ammonia levels did not lead to any
effects on food intake, growth, or mortality relative to LPD-fed mice transplanted with normal
feces who had much higher levels of fecal ammonia. Since patients with hyperammonemic inborn
errors of metabolism are placed on a LPD to prevent metabolic crises, our observations provide
preliminary evidence that the engineering of gut microbiota to reduce fecal ammonia production
may be well tolerated in this patient population. However, additional safety studies are needed.
In summary, we show that diet has a significant effect on the ability of a defined microbial
consortium to engineer the composition of the gut microbiota. Specifically, LPD alters the coexclusion of two dominant taxa within the Bacteroidetes phylum. Given the alterations in the
syntropic host-microbiota interactions in nitrogen flux that occur in the levels of urea delivery from
the host to the gut microbiota, the reduced production of ammonia via bacterial urease, and the
99

uptake of ammonia by both the host and the gut microbiota, a LPD may be a particularly
important environmental stressor that will impact upon the composition of an engineered
microbiota. Nevertheless, the functionality of the engineered gut microbiota, as quantified by a
reduction in fecal ammonia levels, remained intact. Together with the absence of detrimental
effects on host physiology in the setting of a LPD, the reduction in fecal ammonia levels via
engineering of the gut microbiota may be an effective therapeutic strategy for patients with
hyperammonemic inborn errors of metabolism.

Methods
Animals
C57B6J female mice 8 to 12 weeks old (The Jackson Laboratory) were used in this
study. Fecal pellets collected from ASF-colonized CB17 SCID mice (Taconic) served as the
source of the ASF innoculum whereas conventionally-colonized C57B6J mice (The Jackson
Laboratory) served as the source of the normal flora (NF) innoculum used in the FMT procedures
as previously described [12]. Fecal homogenates were prepared by diluting 0.1 g feces 10-fold in
PBS. Mice were prepared for FMT by oral delivery of antibiotics in drinking water (1.125 g
aspartame, 0.15 g vancomycin, and 0.3 g neomycin in 300 mL sterile water) for 72 hours. During
the final 12 hours, the water supply was exchanged with a 10% PEG solution (Merck), and the
mice were fasted. Mice were then inoculated daily with fecal homogenates by oral gavage for 7
days. All mice were housed five per cage in a conventional specific-pathogen free (SPF) facility
(and transferred from one conventional facility to another conventional facility within the University
of Pennsylvania 10 weeks after the start of experiment for NMR imaging) and fed irradiated AIN76A (Research Diets D10001, 21% protein by kilocalories – NPD, see Sup. Table 5.1). After one
week, ten mice were switched to irradiated AIN-76A with lower protein content (Research Diets
D08092201, 3% protein by kilocalories – LPD, see Sup. Table 5.1). Fecal pellets were collected
at baseline on NPD, 10 weeks after placement on LPD, 2 weeks after FMT (15 weeks on LPD), 4
weeks after FMT (17 weeks on LPD), and 10 weeks after FMT (23 weeks on LPD) for bacterial
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taxonomic and biochemical analyses. Fecal pellets were collected in 1.5 mL microcentrifuge
tubes (Sigma-Aldrich) and immediately placed on dry ice then stored in -80°C freezer until time of
analysis. Body composition was determined using NMR imaging via the Mouse Phenotyping,
Physiology and Metabolism Core at the University of Pennsylvania. All animal studies were
performed with the approval of the Institutional Animal Care and Use Committee of the University
of Pennsylvania (Protocol Number: 803408).
16S V1-V2 sequencing
DNA was isolated from stool as previously described [2, 42]. 100 ng of DNA was
amplified with barcoded primers annealing to the V1-V2 region of the 16S rRNA gene (forward
primer, 5′-AGAGTTTGATCCTGGCTCAG-3′; reverse primer, 5′-CTGCTGCCTYCCGTA-3′; [43,
44] using AccuPrime Taq DNA Polymerase System with Buffer 2 (Life Technologies). PCR
reactions were performed on a thermocycler using the following conditions: initiation at 95°C for 5
min followed by 20 cycles of 95°C × 30 s, 56°C × 30 s, and 72°C × 1 min 30 s, then a final
extension step at 72°C for 8 min. The amplicons from each DNA sample, which was amplified in
quadruplicate, were pooled and purified with Agencourt AMPure XP beads (Beckman Coulter)
following the manufacturer’s instructions. Purified DNA samples were then sequenced using the
454/Roche GS FLX Titanium chemistry (454 Life Sciences).
16S rRNA gene sequence analysis
16S rRNA gene sequence data was processed with QIIME v 1.8.0 [45] using default
parameters. Sequences were clustered into operational taxonomic units (OTUs) at 97% similarity
and then assigned Greengenes taxonomy [46] using the uclust consensus taxonomy classifier.
Sequences were aligned using PyNAST [47] and a phylogenetic tree was constructed using
FastTree [48]. Weighted and unweighted UniFrac [49] distances were calculated for each pair of
samples for assessment of community similarity and generation of principal coordinate analysis
(PCoA) plots. Statistical analyses for bacterial abundance difference was performed using non101

parametric Wilcoxon test, and p-values were corrected for multiple comparisons using the
Benjamini and Hochberg procedure.
Measurement of fecal ammonia
Fecal ammonia concentrations were determined using an Ammonia Assay Kit (ab83360,
Abcam, Cambridge, MA). Fecal pellets were suspended in the assay buffer provided at a
concentration of 1 mg/10 uL, homogenized, and centrifuged at 13,000 x g for 10 minutes at room
temperature to remove insoluble material. Ammonia concentration was then determined
according to the kit protocol.
Measurement of serum and fecal urea
Urea concentrations were determined using the QuantiChrom™ Urea Assay Kit (DIUR500, Bioassay Systems, Hayward, CA). Serum samples were assayed directly. Fecal pellets were
suspended in ddH2O at a concentration of 1 mg/10uL, homogenized, and centrifuged at 2,500 x g
for 10 minutes at room temperature to remove insoluble material. Urea concentration was then
determined according to the kit protocol.
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Figures
Figure 5.1. Changes in murine physiology and nitrogen metabolism on a LPD. Differences
in (A) body weight (n=5 in NPD group, n=10 in LPD group), (B) % fat mass, (C) % lean mass, and
(D) serum urea levels between NPD-fed and LPD-fed mice. (E) Fecal urea and (F) fecal ammonia
levels at baseline on the NPD and after placement on the LPD. Values represent mean ± SEM.
Statistical significance in body weight determined by two-way ANOVA with repeated measures;
statistical significance in other parameters determined by paired and unpaired two-tailed
Student’s t test. *p<0.05, **p<0.01, ***p<0.001.
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Figure 5.2. Effect of a LPD on the composition of the gut microbiota. Principal coordinates
analysis (PCoA) ordination of mice before and after placement on the LPD for 10 weeks.
Changes in community membership were analyzed using (A) weighted and (B) unweighted
Unifrac. (C) The interquartile range of Shannon diversity values is shown for mice on the NPD
who were later put on the LPD (Wilcoxon rank sum test p-value = 0.0001299). (D) Heatmap
showing the relative abundance of bacterial lineages over time in mice who were on the NPD at
baseline and then after ten weeks on the LPD. Rows indicate bacterial lineages annotated at the
class taxonomic level on the left. The color key on the right of the figure indicates relative
abundance. Columns summarize the sequencing results from individual fecal specimens. Each
column represents a different mouse. The columns are grouped by diet. (E) Bacterial lineages
that change on the LPD. Four bacterial classes significantly differed between the NPD and LPD
(FDR-corrected Wilcoxon test p-value < 0.05). Relative abundance of each class in both diet
groups is shown. Box and whiskers show the interquartile range; black circles mark the outlier
samples.

A

B
Weighted Unifrac Ordination
PC2 (17.8%)

Unweighted Unifrac Ordination
PC2 (15.3%)

Baseline on NPD
10 weeks on LPD

PC1 (43.1%)

C

PC1 (21.6%)

E

Firmicutes Erysipelotrichi

Firmicutes Clostridia
q=0.027

0.05

4.2

0.75

4.0

0.70

0.03

0.65

0.02

0.60

0.01

3.8

D

Baseline
on
NPD

10 weeks
on
LPD
1

Other Bacteria
Actinobacteria Coriobacteriia
Bacteroidetes Other
Bacteroidetes Bacteroidia
Firmicutes Other
Firmicutes Bacilli
Firmicutes Clostridia
Firmicutes Erysipelotrichi
Proteobacteria Alphaproteobacteria
Tenericutes Mollicutes
10 weeks on LPD

0.00
Tenericutes Mollicutes

Actinobacteria Coriobacteriia
q=0.027

q=0.002

0.020

0.03

0.6

0.02

0.010

0.01

0.005

0.2
0

104

q=0.009

0.04

0.8

0.4

Baseline on NPD

Proportion

Shannon
Diversity

p=0.00013

0.015

0.000

0.00
Baseline
on
NPD

10 weeks
on
LPD

Baseline
on
NPD

10 weeks
on
LPD

Figure 5.3. Effect of a LPD on the initial engraftment of ASF and subsequent resilience
over time. Principal coordinates analysis (PCoA) ordination of mice after transplantation with
ASF. Changes in community membership were analyzed using (A) weighted and (B) unweighted
Unifrac. Dietary groups are color coded as indicated with the shades of colors indicating
progression in time. Day 0 samples have gray circles around them (solid for NPD, dashed for
LPD). The arrows were added to help visualize the progression of time after ASF transplantation.
(C) The interquartile range of Shannon diversity values are shown for mice on the NPD and LPD
inoculated with either ASF or Normal Feces (NF). Black circles mark the outlier samples.
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Figure 5.4. S24-7 returns after ASF transplantation into mice on a LPD but not on a NPD.
(A) Relative abundance of bacterial taxa are shown. Each column represents a single sample of a
pre-treated, ASF-inoculated mice on the LPD (LPD + ASF). Progression of inoculation is shown
across multiple days post inoculation with ASF. Relative abundance of (B) Parabacteroides
(including ASF 519) and (C) S24-7. Box and whiskers show the interquartile range; black circles
mark the outlier samples.
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Figure 5.5. ASF transplantation alters colonic urea nitrogen recycling without significantly
affecting host physiology. (A) ASF transplantation reduces fecal ammonia below the level
achieved by the LPD alone (n=4-5 per group, *p<0.05 compared to baseline, **p<0.01 compared
to 10 weeks on the LPD). (B) No difference in fecal urea level between ASF- and NF-transplanted
mice (n=2-5 per group, *p<0.05 compared to baseline, **p<0.01 compared to baseline). No
difference in (C) body weight or (D) food intake between ASF- and NF-transplanted mice (n=5 per
group). Values represent mean ± SEM. Significance determined by two-tailed Student’s t-test.
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Sup. Figure 5.1. Diversity in each mouse after a LPD. Shannon diversity is shown for all ten
mice while on the NPD (blue) and after ten weeks on the LPD (salmon).
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Sup. Figure 5.2. Principal coordinates analysis ordination of mice on the LPD after
transplantation with ASF or NF. Changes in community membership were analyzed using (A)
weighted and (B) unweighted Unifrac.
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Sup. Figure 5.3. Relative abundance of bacterial taxa after ASF transplantation. Each bar
represents a single sample. Samples represent pre-treated ASF-inoculated mice on the NPD
(NPD + ASF). Progression is shown across multiple days post-inoculation with ASF.
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Sup. Figure 5.4. Murine mortality on a LPD. Kaplan Meier curve showing no significant
difference in survival between ASF- and NF-transplanted mice on the LPD (n=5 per group at start
of experiment).
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CHAPTER 6: Transfer of Viral Communities between Human Individuals during
Fecal Microbial Transplantation.
The contents of this chapter have been published as:
Chehoud C, Dryga A, Hwang Y, Nagy-Szakal D, Hollister E, Luna R, Versalovic J,
Kellermayer R, Bushman F. 2016. Transfer of Viral Communities between Human
Individuals during Fecal Microbial Transplantation. mBio (PMID: 27025251).

Abstract
Fecal microbiota transplantation (FMT) is a highly effective treatment for refractory Clostridium
difficile infections. However, concerns persist about unwanted co-transfer of pathogenic microbes
such as viruses, which has not previously been investigated. Here we study FMT from a single,
healthy human donor to three pediatric ulcerative colitis patients, each of whom received a course
of 22 to 30 FMT treatments. Viral particles were purified from donor and recipient stool samples
and sequenced; the reads were then assembled into contigs corresponding to viral genomes or
partial genomes. Transfer of selected viruses was confirmed by quantitative PCR. Viral contigs
present in the donor could be readily detected in recipients, with up to 32 different donor viral
contigs appearing in a recipient sample. Reassuringly, none of these were viruses are known to
replicate on human cells. Instead, viral contigs either scored as bacteriophage or could not be
attributed taxonomically, suggestive of unstudied phage. The two most frequently transferred
gene types were associated with temperate phage replication. Also, Siphoviridae, the group of
typically temperate phages that includes phage lambda, were found to be transferred with
significantly greater efficiency than other groups. Based on these findings, we propose that the
temperate phage replication style may promote efficient phage transfer between human
individuals. In summary, we documented transfer of multiple viral lineages between human
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individuals through FMT, but in this case series none were from viral groups known to infect
human cells.

Introduction
Fecal microbiota transplantation (FMT) has been used to treat relapsing Clostridium
difficile infection with great success and shows promise for other indications (1, 2). However,
many pathogenic human viruses are known to be transmitted via the fecal-oral route, and viral
transfer accompanying FMT has not been studied previously. Here we investigate viral transfer
during FMT using model-independent metagenomic sequencing.
Introduction of single viruses into humans has been closely studied, but the transfer of
populations of viruses is much less well-understood. Multiple viruses are commonly found as coinfections in humans, though it is usually unknown whether acquisition of these viruses was
sequential or simultaneous. Careful tracking of transmitted founder viruses during HIV and HCV
transmission has revealed examples of probable simultaneous transfer of multiple lineages (3, 4).
HIV and HCV commonly co-occur and may be acquired simultaneously during intravenous drug
use (5). For the case of satellite viruses (e.g. Hepatitis B and its satellite virus Hepatitis D) the two
are inferred to commonly infect together because the satellite depends on its helper for replication
(6). Multiple viruses that replicate in human cells may be transferred together during organ
transplantation (7). For bacterial viruses, simultaneous acquisition of multiple lineages has rarely
been investigated.
The human fecal virome is immense in the numbers of viruses present—comparable to
the number of bacteria, which is 10
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per gram of feces—and the number of different types. Gut

bacteriophages are so numerous and diverse that sequence databases contain only a small
fraction of the global population (8-14). Thus, simply sequencing total DNA from stool and
aligning to database genomes generally misses most of the bacteriophage sequences present,
necessitating specialized methods.
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In this study, we investigated the transfer of viral communities between humans through
FMT and characterized features associated with particularly efficient transmission. We took
advantage of a case series where feces from a single donor were used to treat three children with
ulcerative colitis (UC) (15). These subjects received a particularly intensive procedure, which
consisted of 22 to 30 FMT treatments per subject delivered by colonoscopy or enema during a 6
to12 week period. We performed metagenomic analysis of viral particle fractions purified from
fecal samples from the donor, the donor product, and recipients before, during, and after
transplantation. To track viral transfer, we assembled contigs representing viral genomes and
monitored their abundances through the transplantation process. All recipients were detectably
colonized by multiple donor viruses, documenting transfer of whole viral populations. None of the
transferred viruses were from groups known to replicate on human cells, supporting the safety of
the FMT procedure in this application.

Results
Subjects studied
Three pediatric UC patients receiving immunotherapy regimens were switched to
receiving a course of 22 to 30 FMT treatments via colonoscopy or enema during a 6 to12 week
period (Figure 6.1A) (15). Donor stool specimens were from a single, healthy, 37-year-old male.
FMT in all three patients was associated with a symptom-free period of at least 4 weeks,
supporting the temporary withdrawal of immunotherapy (no treatment other than mesalamine).
Treatment was associated with endoscopic and histologic remission for at least 2 weeks after the
last FMT. All three subjects eventually relapsed and resumed therapy with immunomodulators.
Analysis of transfer of bacterial lineages
Bacterial microbiota composition was investigated by purifying DNA from stool and
sequencing a segment of the 16S rRNA gene as described (15). The donor samples contained
high levels of Bacteroides and lower levels of Firmicutes such as Dialister and Subdoligranulum.
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Prior to FMT, the three recipients harbored communities dominated by Subdoligranulum,
Prevotella, and Bacteroides respectively. During FMT, Bacteroides dominated in all three
recipients (Figure 6.1B). After completion of the FMT treatment, Bacteriodes persisted, but
Firmicutes lineages also increased in abundance in recipients 2 and 3. Global community
analysis showed that for all three recipients, microbial communities during FMT became
detectably (though modestly) closer to that of the donor. After FMT, all three recipients’ microbial
communities increased in diversity (Sup. Figure 6.1), suggestive of acquisition of healthier
microbiota.
Composition of the fecal virome in donors and recipients
To study viral transfer, virus-like particles (VLPs) were purified from 18 samples. We
compared four donor samples of two types: two were crude stool samples and the other two were
processed to generate the liquid product used for FMT. Recipient samples were taken prior to
th

FMT, during the FMT intervention (after the 13 FMT treatment), and after the FMT was
completed. The five control samples were 1) a stool sample from a healthy 25-year-old male, 2)
two stool samples from pediatric Crohn’s Disease patients on immunotherapy but not receiving
FMT, and 3) two buffer only negative control samples. The first three control samples were from
well-studied subjects and serve as positive controls. The two pediatric Crohn’s Disease patients
were selected because a previous metagenomic study had shown them to harbor Anelloviruses
(Torque Teno virus) and Parvoviruses (Human Bocavirus) (16). The two buffer controls were
included to document contamination from reagents and environmental admixture.
VLPs were purified from the 18 samples, then DNA isolated from the particles. VLP DNA
was amplified using multiple displacement amplification (MDA) and the product sequenced using
Illumina technology. Quantitative PCR for 16S was used to assay contaminating bacterial DNA,
documenting only low level carry over (Sup. Table 1). Here we only investigate DNA viruses.
RNA viruses are less abundant in stool than DNA viruses, and previous studies from us and
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others suggest that many of the RNA viruses present in stool are transient plant RNA viruses
derived from food ((17) and unpublished).
At least one million reads were acquired from each fecal sample (Sup. Table 2), allowing
detailed investigation of the viral populations. Low quality reads were filtered out, as were reads
mapping to the human genome (hg18) and phage phiX174 (the latter is added to sequencing
mixtures for technical reasons). Reads were aligned to a curated viral database (18) using a
-3

permissive alignment threshold (BLAST e-value 10 ). After filtering out low abundance negative
control samples (<50,000 reads) plots of the proportions of the most abundant taxa are shown
(Figure 6.1C). The majority of reads did not align to reference database sequences (an average
of 17.9% of reads returned significant matches).
Of the reads that did align, the most common assignments were Microviridae, which are
non-enveloped, single stranded DNA phages from the family including phiX174, and
Caudovirales, which is a broad family including all of the tailed phages. Of the two controls with
known animal cell viruses, Anelloviruses were recovered efficiently, and Bocavirus less efficiently.
The MDA step is known to amplify single stranded circular DNA particularly efficiently, likely
explaining the abundance of Anelloviruses and Microviridae, both of which have small single
stranded circular DNA genomes.
To examine the VLP genomes in our samples more fully, reads were assembled into
contigs using deBruijn graph assembly (19) and overlap consensus methods (20). A total of 3634
contigs were built from the four donor samples (Sup. Table 3). Of these, 261 were greater than
3000 base pairs in length (mean length 8161 bp and maximum length 65335 bp). For the
recipients, a total of 486, 1177, and 1936 contigs were built from each pre-FMT sample; of these
contigs, 38, 138, and 127 contigs were greater than 3000 base pairs (Sup. Table 4). These
contigs were assessed for length, circularity, and number of open reading frames (ORFs). Nine of
the 261 contigs were circular, suggesting that we had sequenced the entire viral genome (Sup.
Figure 6.2). With one exception, these clustered at specific lengths suggestive of Anelloviruses
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(~3000 bp), Microviridae (~5000-6000 bp), and Siphoviridae (typically >30000 bp). One circular
contig (8662 bp) was annotated as Podoviridae (typically >40000 bp), suggesting it may have
assembled as a circle due to the presence of a repeated sequence. Linear contigs are either
complete linear genomes or genome fragments.
Proteins encoded in the gut virome
To catalog the genes present, open reading frames (ORFs) were predicted, conceptually
translated and aligned to several protein databases (19, 21, 22), including one composed of
conserved protein domains (from the Conserved Domains Database (CDD)) known to be
associated with viruses (12, 14). A total of 3,321 ORFs were predicted. Protein types found in the
donor and in each recipient pre-FMT are summarized in Figure 6.1D. Only an average of 7.3% of
proteins were annotated, which emphasizes the size of the pool of uncharacterized
bacteriophage genes. Prominent CDD types were associated with phage capsids, tails, portals,
terminases and other structural components. Additional annotations were associated with effector
proteins including bacteriocin, beta-lactamase, reverse transcriptase, and restriction modification.
Contigs of length >3000 bp had on average 6 ORFs, allowing us to use gene family
membership to annotate the probable viral family of origin. We found that on average each contig
-5

had two ORFs matching a viral genome (BLAST e-value 10 ). The majority of classified VLP
genomes belonged to tailed phages (Caudovirales), which include Siphoviridae, Myoviridae, and
Podoviridae. Microviridae were also prominent. In several cases single ORFs annotated as
belonging to animal cell virus lineages (Poxviridae, Adenoviridae, and Herpesviridae), but multiple
other ORFs on the same contig annotated as Caudovirales, so in these cases the Caudovirales
attribution was retained, or multiple other ORFs were unclassified weakening the validity of an
animal cell lineage. The two Crohn’s disease samples pre-selected for containing animal cell
viruses returned contigs representing Anellovirus and Bocavirus as expected.
Transfer of viral lineages with FMT
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We then used the contigs of >3000 bp to investigate the transfer of phages during FMT
(Figure 6.2, Sup. Figure 6.3). To score detection of a donor contig in a recipient, we required
>50% coverage of the contig and alignment of at least 5 paired reads, where both reads in each
pair showed high quality alignment to the target contig. We note that these criteria are
conservative, so the numbers of contigs transferred represent minimal estimates. Comparing to
recipient samples at the first time point after initiation of FMT, while FMT was ongoing, we
detected 21, 42, and 16 donor contigs respectively. At the second time point, 5 to 13 weeks later
and 2 to 4 weeks after the completion of the FMT treatment, we detected 5, 7 and 34 donor viral
contigs, respectively. Sup. Figure 6.4 shows examples of sequence alignments of reads from
recipients at time points following transfer onto contigs built from donor reads, illustrating high
coverage.
To confirm the transfer from the donor to recipients, we used quantitative PCR (qPCR) to
analyze VLP DNA samples (Figure 6.3). As template we analyzed fecal VLP DNA specimens that
were not subjected to MDA amplification, which is known to distort relative abundances. To
confirm that some lineages transferred efficiently, we analyzed four VLP contigs from the donor
that were detected in at least two different recipients. QPCR assays were designed for each of
the four contigs (Sup. Table 5), and positive control DNAs were synthesized for use as copy
number standards. We compared results for the four donor samples to the nine recipient samples
(three patients, three time points each). We also tested the same positive controls used in the
viral sequencing analysis, specifically stool VLP DNA from a healthy 25-year-old male and two
pediatric Crohn’s Disease patients. As a negative control, we used a commercial phage lambda
DNA sample.
All four qPCR assays detected the expected contigs in the donor samples and in at least
two recipients. Levels were low in all controls. For contig 100-94 (annotating as Microviridae) and
100-182 (Unattributed) donor contigs were detected after FMT in all three recipients (Figure 6.3A
and 6.3B). For contigs 100-21 (Podoviridae) and 19 (Myoviridae), transfer was robust to subjects
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2 and 3 (Figure 6.3C and 6.3D). The maximum copy numbers detected were in the range of 83

15X10 copies per nanogram of VLP DNA.
Viral features associated with efficient viral transfer
We next investigated features of viral contigs associated with efficient transmission
during stool transplantation. We first asked whether any inferred phage-encoded proteins could
be identified that correlated with efficient transmission. Figure 6.4A shows the top two conserved
domain families that correlated with frequency of transmission (p-values<0.05, odds ratio >4.2
times more likely to be transferred). These transferred domains were found to be associated with
the temperate replication style, in which phages form quiescent long-term associations with their
bacterial hosts. The highest scoring family (pfam01051) is annotated as “initiator replication
protein”. The best-studied member of this group is RepA protein of the temperate phage P1.
RepA initiates DNA replication on the P1 genome, and related proteins also mediate replication of
Herpes viruses. The second highest scoring family (pfam14659) is a domain from the lambda
integrase family of integration proteins. Lambda integrase is well known to mediate integration
during prophage formation. Thus both the analysis of preferential transfer of viral family types and
transfer of viral genes indicated preferential transmission of temperate phage.
We next asked whether any viral families were preferentially transferred by comparing
frequencies in the donor versus recipient VLP populations. We focused the analysis on our most
accurate detections, specifically the donor viral pool consisting of contigs >3000 bp. Comparison
showed that Siphoviridae were significantly more likely to be transferred (p=0.0072 by Fisher’s
exact test, Figure 6.4B). We repeated these tests by looking at Siphoviridae compared to all
contigs and again found Siphoviridae to be significantly more likely to be transferred (p<0.0001 by
Fisher’s exact test, Figure 6.4C). Siphoviridae include phage lambda, 434, and P22 and are
known to include viruses with the capacity to integrate into host genomes (23).
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To confirm transfer, we selected four contigs annotating as Siphoviridae and called as
transferred, and designed qPCR assays to verify transfer. VLP DNA samples (not subjected to
MDA) were tested, and contigs were detected in the donor and recipient as expected from the
sequencing data (Figure 6.4 D-G). In all four cases, the transferred phage were detected in at
least two out of the three recipients, indicating transfer to multiple individuals.

Discussion
Here we report transfer of gut viral communities associated with FMT. No viruses
infecting human cells were detected in the donor, so reassuringly no transfer could be
documented in recipients. Numerous recipient VLP sequence reads showed high quality
alignments to donor VLP contigs, suggesting transfer with FMT. Many annotated as containing
genes known to be phage encoded, supporting the inference that the VLP contigs corresponded
to phage. From 5 to 34 transferred contigs could be detected in recipient samples. Simultaneous
transfer of multiple viruses has rarely been documented in humans but was readily detected here,
potentially associated with the large number of FMT treatments (22 to 30 per subject). Based on
these observations, we propose that transfer of bacteriophage populations is a general
characteristic of FMT.
An alternative interpretation for our data could be that viruses were not transferred from
donor to recipients, but instead were present in recipients initially below the level of detection.
According to this view, viruses pre-existing in the recipient would have grown out after FMT,
resulting in spurious appearance of transfer. We cannot completely rule this out, but several
aspects of phage biology in the human gut support our interpretation. Bacteriophage populations
in the intestines of healthy humans are known to show extreme differences among individuals (814). However within an individual, populations show notable longitudinal stability, at least in
healthy subjects (8, 10, 11). As a result, most VLP genomes are likely recognizable by their
individual of origin. Thus, while it is possible that some new detections in recipients represent the
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outgrowth of pre-existing viruses, or even de novo colonization, we expect that most recipient
sequences resembling donor VLPs are genuinely derived from the donor stool product.
Our most unexpected finding was that lysogeny is associated with efficient transfer by
FMT. This was indicated first by the preferential transfer of the Siphoviridae, the group including
the well-studied temperate phage lambda. Analysis of genes associated with transfer also made
this point (Figure 6.4A). The most strongly associated gene encoded the RepA protein, important
for replication of the temperate phage P1, and the second, encoded a domain of the lambda
integrase proteins important for prophage formation.
Based on our findings, we propose that the temperate phage replication style may have
evolved in part to optimize phage transmission between environments. If bacteriophage must
pass through hostile environments to reach locations favorable for replication, transportation as a
prophage may promote dispersal. Transmission of gut viruses between human hosts potentially
involves persistence outside the gut, likely representing a transmission barrier. Viruses
transferred efficiently by the fecal-oral route are rarely enveloped, suggesting that tough physical
properties may be needed to survive fecal-oral transmission. In feces, an enveloping membrane
may be damaged by the detergent effects of bile salts or by drying after shedding in feces.
Respiratory viruses, in contrast, are commonly spread on respiratory droplets and are often
enveloped. Integration of prophage DNA into the bacterial genome may provide a protective
vehicle supporting phage transmission despite exposure to feces or other hostile environmental
pressures. Thus, we propose that the temperate phage replication style may in part have evolved
to maximize survival during transmission.
In summary, we presented a metagenomic survey of DNA viruses transferred during
FMT. Numerous temperate phage were found to be transferred, but no viruses detected
corresponded to pathogenic viruses that infect human cells. Methods for preparing and
introducing feces into patients vary and may influence the likelihood of viral transmission, so
additional characterization of viral transfer can help guide development of safest practices.
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Methods
Human subjects
Human subjects and methods used for FMT have been described (15). As stated in the
supplemental methods, fresh stool specimens from the healthy adult donor were aliquoted to ~50
g aliquots. Cold sterile normal saline solution was added prior to homogenization in a strainer bag
with 500-µm pore size (Seward Laboratory Systems Inc., Port Saint Lucie, FL) using the Smasher
Laboratory Blender/Homogenizer (AES CHEMUNEX Inc., Cranbury, NJ). Both fresh stool
samples and the homogenized stool preparations which were used for the transplantation were
analyzed in this study. Experiments were carried out under a protocol approved by the
Institutional Review Board of Baylor College of Medicine (H-30591).
DNA purification and sequencing
Detailed methods are presented in the Supplemental Material and summarized here.
Phage particles were purified from stool samples by suspension in SM buffer and filtration
through a 0.22  µm filter (EMD, Millipore). The filtrate was concentrated using the 100  kDa
molecular weight cutoff filter Centricon Plus 70 (Millipore), resuspended in 40  mL Buffer SM, and
concentrated. The concentrate was treated with DNase I and RNase (Roche) at 37°C for 30  min
to eliminate non-encapsulated nucleic acids, then the enzymes were deactivated at 65°C for
15  min. Total phage DNA was extracted from particles using the QIAamp DNA Stool Kit (Qiagen).
Extracted phage DNA was amplified using Illustra GenomiPhi V2 DNA Amplification Kit (GE
Healthcare). Libraries were made using the Illumina Nextera XT Samples Prep Kit and quantified
using the SYBR Fast Illumina Library Quantification Kit (Kapa Biosystems).
Purified VLP DNAs were sequenced on three MiSeq runs (250 base per read, paired-end
sequencing) according to manufacturer’s instructions (Illumina). Two negative control samples
yielded 1242 and 36156 reads respectively. Contigs were built from the four donor samples and
were annotated with open reading frames (ORFs), integrase genes, and viral family names based
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on similarity to reference viral genomes. ORFs were also aligned to a database of conserved
domain integrase genes (to assess potential temperate replication style), and also the Virulence
Factor Database, Aclame database of mobile genetic elements, NCBI’s reference viral database,
NCBI’s reference bacterial database, and NCBI’s nucleotide database to assess additional
functional features (summarized in Supplemental Tables 3 and 4). Reads from all of the samples
were mapped to contigs built from the four donor samples using Bowtie2 (24). Coverage metrics
were calculated, including concordance rate between paired reads, average depth of coverage,
and the percentage each contig was covered by reads.
QPCR validation
The qPCR for quantitating contigs was performed using FastSYBR Green Master Mix
(Applied Biosystems). Primers are described in Supplemental Table 5. The ZeroBlunt TOPO
Vector (ThermoFisher Scientific), containing the corresponding gBLOCK synthetic copy number
control sequence, was linearized and used as a standard control.
Quantification of 16S rRNA copy number was performed using the real-time TaqMan
method with TaqMan® Environmental Master Mix 2.0 and primers as indicated in Supplemental
Table 5. The ZeroBlunt TOPO Vector containing a near full-length clone of Escherichia coli 16S
was linearized and used as a standard control.
Statistical analysis
Fisher’s exact test and odds ratios were used to assess significance of conserved
domains or viral family transfer.
Assessing contamination of phage DNA preparations with bacterial and human DNA
Purities of the phage DNA preparations were assessed using qPCR to quantify bacterial
16S rRNA gene copies (Sup. Table 6.1). Values ranged from 7 to 5021 16S rRNA gene copies/ng
of purified phage DNA (average of 257 copies/ng). The contribution of bacterial DNA per
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nanogram of purifed phage DNA could be estimated by assuming the average bacterial genome
9

9

has 2 to 5 rRNA gene copies and is 2.5 to 5.5 Mb (25) total (MW 1.6 x 10 to 3.3x10 ), implying
that implying that on average 1.0 nanogram of phage DNA was contaminated with 1.1 picograms
of bacterial DNA.
Human DNA contamination was also assayed by aligning sequence reads from the VLP
DNA samples to the human genome. Most samples contained <1% human DNA; the highest
value recorded was 4% (Sup. Table 2). We thus conclude that bacterial and human DNA were
minor contributors to the VLP genomic DNA samples studied.

129

Figures
Figure 6.1. Fecal microbiota transplantation (FMT) to treat ulcerative colitis. A) Diagram of
the treatment regimens. Patient 1 received 30 rounds of FMT, Patient 2 received 25, and Patient
3 received 22. All patients were in remission (gray shaded box) while receiving the FMT course
and remained in remission for more than 11 weeks following their last FMT. However, all three
eventually experienced a relapse requiring immunotherapy. Mesalamine, given orally or through a
rectal enema, was allowed during the trial, depending on clinical disease activity. Three samples
(indicated as triangles) were taken from each patient: one before the beginning of the FMT
th
course (pre), the second after the 13 FMT (during), the third two to three weeks after finishing
the FMT course (post). B) Bacterial lineages in the samples studied. Bacterial taxonomic
representation and abundance was characterized by sequencing of 16S rRNA gene tags. Details
are described in (15). C) Viral families detected in the samples studied, assessed by alignment of
reads to a curated database of viral sequences from (18). D) Gene types inferred from analysis of
the VLP contigs. VLP contigs were analyzed for open reading frames (ORFs), then ORFs
annotated using CDD. Output was interpreted using custom annotation relating pfam domains to
viral gene functions. Gene types identified are summarized to the right of the figure. Percentage
of classified phage ORFs was 8.9%, 7.1%, 3.8% and 9.5% respectively.
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Figure 6.2. Transfer of phage between human individuals. Transmission is shown using
Sankey diagrams. The patients 1-3 are shown from top to bottom. For each subject, contigs
>3000 bp are shown as the box at the left, with recipient contigs on top and donor contigs below.
In the middle, contigs detected at the during FMT time point are shown, to the right are contigs
detected after cessation of FMT (post). Curves with darker colors show persistence of donor
contigs, curves with lighter colors persistence of recipient contigs. The color of each strand
represents a single viral family. Numbers indicate the number of donor contigs transferred from
each viral family.
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Figure 6.3. Analysis of repeatedly transferred VLP contigs by qPCR. VLP contigs built from
donor samples that are indicated by sequence data to be present in patients after FMT treatment,
but not in recipient pre-FMT samples, were quantified by qPCR. VLP DNA from stool was tested
without use of Genomifi Amplification (to reduce distortions of abundance). Abundance was
quantified from 4 samples from the donor (two whole stool and two purified product prepared for
FMT), the 3 recipient patients at three time points each, and 3 control individuals. As a negative
control, Lambda DNA was also tested (far right). The dashed line along the baseline indicates the
inferred background level in the lambda DNA negative control. Contig length, circularity, and viral
lineage as attributed by ORF annotation is indicated on each panel. A) Contig 100-182
(unattributed); B) Circular Contig 100-94 (Microviridae); C) Contig 100-21 (Podoviridae); D)
Contig 19 (Myoviridae).
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Figure 6.4. Preferential transfer of Siphoviridae between human individuals. A) Top
differentially transferred genes based on CDD annotation in the pfam database. A total of 302
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CDD hits were found in the contigs. The top two domains (p-value < 0.05, odds ratio > 4) based
on CDD annotation which were most frequently transferred are shown. B) Comparison of the
frequency of transfer to least 2 of the 3 patients for Siphoviridae contigs versus all others contigs
>3000 bp. Here transfer is defined as achieving >50% coverage and >5 paired reads, where both
reads in each pair detect the same contig. If transfer is defined as detection of a donor contig
during FMT, post-FMT, or both in at least one patient, the favoring of Siphoviridae achieves
p<0.0001. C) Comparison of the frequency of transfer to least 2 of the 3 patients for Siphoviridae
contigs versus all other contigs built. D-G) Contigs annotating as Siphoviridae found in the donors
and suggested by sequence data to be transferred to multiple recipients validated using qPCR.
Samples tested and annotation were the same as in Figure 3. D) Contig 100-72; E) Contig 100230; F) Contig 100-176; G) Contig 66.
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Supplemental Information
Supplemental Methods
Classifying viral read
All MiSeq reads were BLAST aligned to a custom database (Norman et al., 2015) using an e-3

value 10 and max_target_seqs 100. All default settings were used unless otherwise stated. The
BLAST outputs (compressed BLAST XML format) were analyzed using MEGAN (Huson et al.,
2011) with the following parameters: minsupport=1, minscore=30.0, toppercent=10.0, and
mincomplexity=0.44. All classifications that did not include a viral family (e.g. “root;Viruses;dsDNA
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viruses, no RNA stage; unclassified dsDNA phages”, “root;Viruses;unclassified
phages;Enterococcus phage EF62phi”) were considered Unclassified. Proportions of the
classified viral families were calculated. Samples with less than 50,000 reads (i.e. two negative
control SM buffer samples) were excluded.
Bacterial data
Previously published bacterial 16S data (Kellermayer et al., 2015) was reanalyzed using
R packages qiimer and vegan. Shannon diversity was calculated for each sample. A principal
coordinate ordination plot, based on the Weighted Unifrac distances, was built. The Weighted
Unifrac distance between each patient sample and the centroid of the donor samples was
calculated.
Assembling, annotating, and visualizing viral contigs
Sequence reads were first assembled into contigs using IDBA-UD (Peng et al., 2012)
with pre-correction and minimum and maximum k-mer lengths set to default 20 and 100 bp
respectively. Minimo (Treangen et al., 2011), a program which utilizes a conservative overlaplayout-consensus algorithm, was used to further combine the contigs. Contigs were built from 1)
all 4 donor samples, including two crude stool samples and two processed samples which were
blended and filtered to generate the liquid preparation used for the FMTs, 2) patient 1 pre-FMT’s
samples, 3), patient 2 pre-FMT samples, and 4) patient 3 pre-FMT samples. Each of the three
patients’ pre-FMT sample (after Genomiphi amplification) was sequenced thrice. The sequencing
data from each patient’s pre-FMT samples was combined.
After the contigs were built, reads from each donor and patient sample were aligned
using Bowtie2 (Langmead and Salzberg, 2012) to each of the four sets of contigs. Bowtie’s verysensitive parameters (i.e. -D 20 -R 3 -N 0 -L 20 -i S,1,0.50) were used. Samtools and bedtools (Li
et al., 2009; Quinlan and Hall, 2010) were used to parse the alignment results and assess
genome coverage.
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In addition to the number of reads matching each of the four sets of viral contigs, length
of the viral contig was determined. The circularity of each contig was also assessed by looking for
at least 10 and at most 1000 bp of overlap between the end and beginning of the contig
sequences that were greater than 3500 bp in length.
Entire contig sequences were then compared using BLAST with an e-value threshold 10
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to NCBI reference viral database, nucleotide (NT) database, and bacterial genomes database
(downloaded January 7, 2015 from NCBI Refseq). Top matches were recorded. Additional “host”
information was given to each contig using the following rules: 1) if a match to a reference viral
database was found, the top match was used, 2) if no match to the viral database was found but
a match to a bacterial genome was found, the match to the bacterial genome was used, and 3) if
no match to the viral or bacterial reference genomes was found but a match was found to the NT
database, that match was used.
Contigs were then annotated with open reading frames (ORFs) using Glimmer (Salzberg
et al., 1998), a program that utilizes the Interpolated Context Model to predict genes. Minimum
gene length was set to 100 bp. The number of predicted ORFs was recorded. Predicted ORFs, in
protein form, were BLAST aligned to ORFs of known viral families. The number of ORFs
matching predicted ORFs from reference viral family sequences was recorded. A putative viral
family was given to each contig based on the viral family with the most ORF matches. For
example, if a contig had 4 predicted ORFs, 3 of which matched ORFs in known Siphoviridae
viruses and 1 of which matched an ORF in a known Podoviridae virus, the contig would be
putatively annotated as belonging to the Siphoviridae family. If only 1 of the 4 predicted ORFs
matched an ORF in a known Siphoviridae virus and the remaining 3 ORFs did not have any
matches, the contig would be assigned to the Siphoviridae family. In the rare instance were an
equal number of ORFs matched two families (e.g. 2 ORFs matched one viral family and another
2 ORFs matched another family), a viral family was selected at random.
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Seven contigs contained ORFs that showed a top blast hit to an animal cell virus ORF. In
all cases, the matched ORFs were a minority of all ORFs on the contig. In 5 out of 7 cases, the
contig as a whole found a better alignment to a phage or bacterial sequence. In the remaining 2
cases, no better matches were found but because the animal cell viruses matched 1 out of 3 or 1
out of 6 contig ORFs, we concluded that these contigs were likely derived from phage or bacteria
as well.
In addition to using ORFs for providing putative viral family names, ORFs were aligned to
conserved domains of integrase proteins with Pfam (Sonnhammer et al., 1998), the Virulence
Factor Database (Chen et al., 2012), and Aclame database of mobile genetic elements (Leplae et
al., 2010). The number of matches to each of these databases was recorded.
Predicted ORFs, in protein form, were also compared to the Pfam (Sonnhammer et al.,
1998) database of conserved domains with Reversed Position Specific BLAST (RPSBLAST). Low compositional complexity regions were not masked and default e-value of 0.01 was
used for the search. Pfam families were grouped using custom database with Pfam domain
identifiers linked to phage regulation function (Minot et al., 2011). Contigs from 1) 4 donor
samples, 2) patient 1 pre-FMT, 3) patient 2 pre-FMT, and 4) patient 3 pre-FMT were annotated
with phage gene types.
Last, the number of reads from each sample mapping to each contigs were plotted. The
size of the circle was set to represent percent of the contig covered by reads from that sample.
The colors of each sample were used to distinguish the donor, each patient, and the control
samples. Contig names were annotated with length and putative viral family (if any).
Donor contigs in patients during and post-FMT
Contig transfer was assessed separately for each patient and and then for all patients
combined. Transfer meant 1) an increase in the number of reads matching a contig in a patient’s
during FMT and/or post-FMT sample(s) from the patient’s pre-FMT sample, 2) at least 5 paired
138

reads matching the contig during and/or post-FMT and 3) at least 50% coverage of the contig
during and/or post-FMT. The number of viral contigs that transferred (as well as the contigs’
putative viral family name) was recorded for each patient. Viral contigs, built from the donor
samples, could have been seen in a patient’s during FMT sample, patient’s post-FMT sample or
both. The number of transfers as well as putative viral family classification was represented using
Sankey plots (using R riverplot package). Contigs that were seen to be transferred in at least 2 of
the 3 patients were also recorded. 2x2 contingency tables were built for each viral family and
transfer, as well as pfams and transfer. Fisher’s exact test, and odds ratio, was used to calculate
significance.
Verification of donor contigs
To verify our sequence results, four contigs were selected for verification with qPCR.
Prior to qPCR, the sequence data from all of the samples was re-aligned to each contig and
visualized using IGV (Robinson et al., 2011). Manual visual inspection confirmed the contig
transfer plots, and qPCR assays were developed. After seeing an overrepresentation of
Siphoviridae being transferred, 4 contigs specifically annotating as Siphoviridae were assessed
for qPCR. Alignment of all sample reads to these contigs was again visualized in IGV and
manually confirmed to match the contig transfer plots.
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CHAPTER 7: Conclusion
This dissertation describes changes in the microbial communities associated with
disease states, how the microbial communities can be modulated to ameliorate certain disease
states, and the possible obstacles of such modulation. Like the microbiome field, in this thesis, we
shift from characterizing and associating microorganisms with disease states to investigating the
possibilities of engineering communities of microorganisms to alleviate diseases. Microbiota
transplantation has been shown to be highly efficacious in treating C. difficile infections, but much
more work is in progress investigating its uses for other disease. We answer fundamental
questions about the long-term durability of transplants in mice and how they are affected by diet.
We investigate the use of microbiota transplants in the treatment of hyperammonemia. We also
investigate the behavior of viruses during transplantations to assess a potential obstacle. This
work serves as an important contribution to the field, particularly as we are just beginning to
harness the power of the microbiome to cure disease.
I begin my dissertation by characterizing the microbial community in two contexts. In
Chapter 2, targeted sequencing was used to characterize the bacterial, archaeal, and fungal
communities in pediatric Inflammatory Bowel Disease (IBD) patients. Similar to previous studies
(1-5), decreased bacterial diversity was observed in pediatric IBD patients. Fungal diversity was
reported to have decreased in IBD patients compared to healthy controls, and one Candida
member, associated with at least five names, including Pichia jadinii, Candida utilis,
Cyberlindnera jadinii, Torulopsis utilis, and Torula utilis (6), was found to be enriched in IBD
patients. Only three pediatric IBD patients had detectable archaea in their stool, and all archaeal
sequences were members of the Methanobrevibacter genus. A random forest classifier was used
to partition pediatric samples by disease status. The greatest accuracy of the classifier, 93
percent, could be achieved when the abundance of both bacterial and fungal community
members was taken into account. This chapter illustrates the importance of investigating fungal
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community members in conjunction with bacterial members, and presents clear evidence that
fungal dysbiosis is present in pediatric IBD.
An important question arising from this study is whether this fungal signature, or a
combination of fungal and bacterial signatures, is useful as a molecular diagnostic tool. To
explore this further, one must first verify that the signatures found in this paper can be
reproduced. Recent studies have found the same Candida organism, also known as Pichia
jadinii, to be in more abundant in IBD patients both via tagged-sequencing and metagenomics
sequencing (7, 8). It is also important to assess whether the fungal signatures observed in
Chapter 2 correlate with parameters such as disease severity, medication success, IBD subtype
etc. This would allow us to determine whether fungal blooms are a response to certain IBD
treatments or if the fungal community membership can help us distinguish between IBD subtypes.
The few Ulcerative Colitis (UC) patients in our study did not allow us to discriminate between the
UC and Crohn’s Disease (CD) phenotype. The number of subjects in the UC subtype would need
to be expanded significantly to better assess differences. If studies continue to support fungal
signatures clearly distinguishing between IBD and healthy patients, correlations between the
fungal signatures and variables such as age, antibiotic usage, medication, immune cells, need to
be performed. This would set the groundwork for follow-up, mechanistic studies that can link fungi
and inflammation within our gastrointestinal tract and help answer questions concerning the role
of specific yeast lineages in the etiology of IBD.
Chapter 3 discusses the characterization of DNA virus in lung-transplant recipients. A
highly abundant and diverse set of anelloviruses was found in the lungs of lung-transplant
recipients. The anelloviruses were verified with Q-PCR and found to be 56-fold more abundant in
lung transplant recipients compared with healthy controls or HIV+ subjects. Novel anelloviruses
were built from the metagenomics data and phylogenetically compared to previously known
anelloviruses. This revealed a vast diversity of anelloviruses, even within single individuals.
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The primary follow-up to this work is to perform long-term longitudinal studies to
determine whether levels of anelloviruses in the lung allograft are associated with, and possibly
play a role in, transplant outcomes. Can we use abundance levels of anelloviruses or anellovirus
diversity to track and predict lung transplant failures? Is this possible with other organ
transplants? A study preceding ours found anelloviruses in serum following organ transplantation
(9). They reported that anellovirus genome levels correlated with the extent of
immunosuppression, suggesting that anellovirus DNA in blood might serve as an assay for the
overall level of immunosuppression. This leads us to ask about the correlation between
anellovirus levels in serum and lung allograft. Are there differences in anelloviruses species in
different body sites within the same person? In addition to looking at anelloviruses, we must
investigate other viruses that may be useful as indicators of immunosuppression. Our current
tools for identifying viruses are biased towards DNA viruses and viruses that amplify well with
Genomiphi. We need to identify others viruses known to be ubiquitous in humans and assess via
targeted Q-PCR how their abundance levels track with immunosuppression. Viral markers can
provide a new wave of clinical immune-monitoring strategies for organ transplant recipients.
In Chapters 4 and 5, we replaced the entire gut microbial community of mice with a
defined consortium of eight bacteria containing minimal urease gene content, known as Altered
Schaedler Flora (ASF). This engineered gut microbiota was able to engraft long-term and reduce
fecal urease activity and ammonia production, leading to decreased morbidity and mortality in a
murine model of hepatic injury. Since the gut microbiota responds differently to environmental
stressors such as diet, we further investigated the effects of dietary protein restriction on the
structure and function the microbiota community engineered by inoculation with ASF. We found
that community membership after the initial ASF inoculation was similar between mice on a
normal protein diet (NPD) and a low protein diet (LPD), but the outgrowth of gut microbiota
differed over the ensuing month. Nevertheless, fecal ammonia levels remained significantly lower
in ASF-transplanted mice on a LPD compared to mice transplanted with conventional microbiota
on a LPD, showing that the functionality of the engineered gut microbiota remained intact. These
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findings provide insight into engineering a gut microbiota with a defined bacterial consortium, and,
how this is affected by diet.
It is widely known that diet is one of many factors that affect our gut microbiota. Although,
we specifically investigated the effect of a LPD versus NPD on the engraftment of an engineered
community, further studies investigating other perturbations are warranted. For example, how
resilient is the engineered community if a new dose of antibiotics is given without an additional
ASF gavage or if a conventional mouse is added to the cage of mice with established engineered
communities? How different are the effects of the perturbations as we get farther away from the
time of the initial ASF inoculation? How does the engraftment change in mice of different genetic
backgrounds? Investigating these questions in the controlled-setting of animal models will help us
predict the dynamics of defined communities in humans.
In Chapter 6, we investigated whether viruses also transfer when microbial communities
are transferred from one human to another. Since fecal microbiota transplantation (FMT) is a
highly successful treatment for relapsing Clostridium difficile infection and, potentially, other
gastrointestinal diseases, we set out to investigate the transfer of viral communities during FMT in
pediatric UC patients. We documented transfer of multiple viral lineages between humans; none
of which were viruses that replicated on animal cells or are known to be pathogenic. We found
that temperate bacteriophage, which form stable associations with their hosts, were significantly
more likely to be transferred during FMT. We conclude that our findings support a model in which
the viral temperate replication style may have evolved in part to support efficient viral
transmission between environments.
The most important follow-up to the work presented in chapter 6 is to develop better tools
to investigate the virome. Most of the viruses we find are novel viruses that cannot be annotated
with taxonomic information. Furthermore, we need to improve the methods by which we can
match viruses with their bacterial hosts. Our current methods include correlating abundance
profile or using genetic homology, CRISPRs, or oligonucleotide profiles (reviewed in (10)). A
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recent paper challenged 74 genetically defined Propionibacterium strains with 15 fully-sequenced
phages to assess phage infection capabilities (11). We should be able to use sequence data
coupled with these types of wet-lab results to build models to predict infectivity of bacteriophage
and bacterial host pairs. With enough data (particularly with experiments investigating how single
polymorphisms can alter infectivity), we should be able to take viral sequences and assign each
nucleotide an importance score. This would allow us to take the data presented in Chapter 6 and
predict whether viruses in a donor’s stool would survive in a recipient’s, as well as use these tools
to investigate viral-bacterial relationships in a wide range of applications.
This dissertation examines a broad range of questions relating to the human microbiome.
I first discuss characterization of fungal, archaeal, and bacterial communities in pediatric IBD
patients and viral communities in lung-transplant recipients. To better understand the dynamics
between different bacteria, I describe studies investigating defined microbial communities in
animal models and end with a study investigating viral communities during FMT in humans. This
entire work took advantage of the capabilities of high-throughput sequencing, which enabled an
unprecedented, large-scale investigation of microbial communities. The methods developed and
discussed in this dissertation will allow other scientists to investigate the bacterial, archaeal,
fungal, and viral communities under a different set of circumstances. The research presented
here is meant to serve as a foundation for subsequent studies investigating the dynamic
microorganisms that live within us.
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